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Abstract
Alterations of DNA repair enzymes and consequential triggering of aberrant DNA damage 
response (DDR) pathways are thought to play a pivotal role in genomic instabilities associated with 
cancer development, and are further thought to be important predictive biomarkers for therapy 
using the synthetic lethality paradigm. However, novel unpredicted perspectives are emerging 
from the identification of several non-canonical roles of DNA repair enzymes, particularly in 
gene expression regulation, by different molecular mechanisms, such as (i) non-coding RNA 
regulation of tumour suppressors, (ii) epigenetic and transcriptional regulation of genes involved 
in genotoxic responses and (iii) paracrine effects of secreted DNA repair enzymes triggering the 
cell senescence phenotype. The base excision repair (BER) pathway, canonically involved in the 
repair of non-distorting DNA lesions generated by oxidative stress, ionising radiation, alkylation 
damage and spontaneous or enzymatic deamination of nucleotide bases, represents a paradigm 
for the multifaceted roles of complex DDR in human cells. This review will focus on what is known 
about the canonical and non-canonical functions of BER enzymes related to cancer development, 
highlighting novel opportunities to understand the biology of cancer and representing future 
perspectives for designing new anticancer strategies. We will specifically focus on APE1 as an 
example of a pleiotropic and multifunctional BER protein.
Introduction
Tumour cells can develop drug resistance via repair mechanisms that 
counteract the DNA damage induced by chemo- and radiotherapies. 
DNA repair enzymes are therefore possible targets for promising 
and novel anticancer strategies (1,2), in which specific DNA repair 
inhibitors are combined with DNA-damaging agents to improve 
current anticancer therapies. In parallel, some cancer cells show a 
reduced repertoire of DNA damage responses (DDRs), which pro-
vide other therapeutic possibilities, relying on the synthetic lethality 
paradigm. Indeed, many polymorphic variants of DDR enzymes 
have been described in the whole population, but their causal link 
with genome instability, associated with tumour development, is still 
controversial. Emerging evidence in tumour biology has shown that 
RNA processing pathways participate in DDR, and that defects in 
these regulatory connections are associated with genomic instability 
in cancers (3,4). Indeed, many DNA repair proteins interact with 
proteins involved in RNA metabolism, non-coding RNA (ncRNA) 
processing and gene transcriptional regulation (5), indicating a sub-
stantial role of the deriving interactome network in determining 
their non-canonical functions, thus impacting gene expression in tu-
mour cells. Moreover, recent studies have shown several interactions 
among DDR components and microRNAs (miRNAs) and, notably, 
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to cancer development (2). Importantly, the molecular mechanisms 
of miRNA processing and/or decay during genotoxic stress are still 
largely unknown, but it is possible that enzymes of the DNA repair 
pathways may be protagonists. We have recently reported that en-
zymes of the base excision DNA repair (BER) pathway play a crucial 
role in these molecular processes (6,7). Due to its function in the 
maintenance of genome stability under conditions of oxidative stress 
as well as exposure to DNA damaging agents used in chemotherapy, 
and its central involvement in transcriptional regulatory circuits, the 
BER pathway represents an unexpected and intriguing opportunity 
to identify novel cancer biomarkers and design new anticancer strat-
egies. These findings prompted us to study the role of BER proteins 
in a different way, to understand their real contribution to the onset 
of cancer. These findings will help us to better understand the role of 
these enzymes from benchtop to bedside using a powerful transla-
tional perspective. This review will focus on what is known of the ca-
nonical (canonical DNA repair of DNA damage) and non-canonical 
functions (transcriptional, immunological, or repair of RNA-decay/
processing) of BER enzymes, to link these functions with the biology 
of cancer.
Focus on the canonical roles of the BER 
pathway in DNA repair and telomere 
maintenance
Exposure to endogenous (i.e. mitochondrial respiration and inflam-
matory processes) or exogenous (i.e. ionising radiation, chemotherapy 
treatment by alkylating agents and antimetabolites) damaging ef-
fectors including deaminating agents, triggers an accumulation of 
non-bulky single base lesions on both nuclear and mitochondrial 
DNA (8,9), which can be efficiently repaired by the BER pathway. 
Thus, this pathway, which is largely conserved from Bacteria to 
Eukaria, preserves genomic integrity (10). The first enzymatic step in 
the BER pathway involves lesion-specific DNA glycosylase activity. 
In mammalian cells, each of the 11 existing N-glycosylase proteins 
differs from the others in its mechanism of action, substrate spe-
cificity and excision kinetics (11–13). Generally, the recognition of 
specific damaged bases occurs through a flipping out mechanism fol-
lowed by a sophisticated process involving excision of the damaged 
base (14), thus leaving an abasic (AP) site. DNA glycosylases are 
classified into mono- and bifunctional glycosylases on the basis of 
the type of recognised damaged site and on the mechanism of action. 
Monofunctional DNA glycosylases, e.g. uracil DNA glycosylases 
(UDG), including the mitochondrial uracil N-glycosylase (UNG1), 
nuclear UNG2 and a single strand selective monofunctional uracil 
DNA glycosylase (SMUG1), process uracil, thymine and alkyl-
ated bases, to cleave the C1-N-glycosidic bond, leaving an AP site 
and liberating a nucleobase. Bifunctional glycosylases, including 
the 8-oxo-7,8-dihydroguanine DNA glycosylase (OGG1), NTH1 
and the Nei-like DNA glycosylase (NEIL) family, cleave oxida-
tive lesions and display, in addition to their glycosylase activity, an 
extra AP-lyase activity (15). As already demonstrated by Hill et al. 
(16) and by our recent work (7), OGG1 activity is stimulated by 
the presence of APE1 endonuclease, an enzyme that acts following 
OGG1 during the BER pathway. After the recognition of damage, 
bifunctional glycosylases use an amine nucleophile, such as a lysine 
side chain, to cleave the N-glycosidic bond, generating a Schiff base 
(imine) intermediate (17). Subsequently, through their AP-lyase ac-
tivity, they cleave the DNA phosphodiester backbone on the 3′ side 
of the lesion, through a β-elimination resulting in a single-strand 
break. Moreover, some of them perform a second cleavage on the 
DNA phosphodiester backbone on the 5′ side of the lesion through 
a δ-elimination process (18). Although the importance of the BER 
pathway has been clearly demonstrated using BER gene knock-out 
models, resulting in embryonic or early postnatal lethality (19), it 
has been reported that a high variety of glycosylases in mamma-
lian cells causes a significant redundancy in their damage selectivity, 
which would explain why a single knock-out of one of the multiple 
DNA glycosylases is not always lethal (14).
After the hydrolysis of the N-glycosidic bond by DNA 
glycosylases, the newly generated AP site must be processed by a 
specific apurinic/apyrimidinic endonuclease (20). Furthermore, a 
spontaneous depurination of DNA also occurs very frequently. It has 
been estimated that, considering only spontaneous hydrolysis of the 
N-glycosidic bond, up to 10 000 abasic sites are formed per day/cell 
in higher eukaryotes (21,22). Unrepaired abasic sites are mutagenic 
and lethal for the cell, so it is clear that their repair is imperative (23). 
In this context, the apurinic/apyrimidinic endonuclease 1 (APE1) is 
the only enzyme having a role in DNA repair (24,25). Embryonic 
lethality as a consequence of the deletion of the ape1 gene high-
lights the importance of APE1, which is not only restricted to the 
BER pathway, but is also related to all its physiological cellular 
functions (26). APE1 is a monomeric protein, structured in a α/β-
sandwich globular fold coupled to a 48-amino acid, unstructured 
part in the N-terminal portion (27). Through its C-terminal globular 
region (residues 61–318), mainly responsible for endonuclease ac-
tivity (28), APE1 specifies the presence of abasic sites among any 
normal nucleoside, principally distorting the DNA backbone with 
an 35°-angled extrahelical distortion (29). When the APE1–DNA 
complex is formed, an additional rearrangement is needed to allow 
the efficient execution of the hydrolytic reaction. The presence of 
Mg2+ (or Mn2+) ions, positioned in the active site of APE1 and prin-
cipally coordinated by the E96 residue, is necessary to promote this 
rearrangement and to allow for cleavage of the AP site (30). The 
excision of the phosphodiester bond, at the 5′ side of the AP-site, 
also requires a water molecule acting as a nucleophile (31). The ac-
tive site of the endonuclease is defined by several residues including 
His-309, Glu-96, Asp-283, Thr-265, Tyr-171, Asn-68, Asp-210, Asp-
70 and Asn-212, which are mostly involved in hydrogen bonding 
(31–33). Through this pocket site, APE1 is also active on damaged 
single-stranded DNA (ssDNA), suggesting a possible role in tran-
scription, replication and/or recombination (34). Furthermore, in 
vitro studies have demonstrated the capability of APE1 to act as a 
3′ DNA phosphatase and 3′→5′ DNA exonuclease on mismatched 
deoxyribonucleotides located at the 3′-end of nicked or gapped 
DNA (35–37). Recently, great importance has also been ascribed to 
the APE1 N-terminal region (1–127 residues), which is responsible 
for protein–protein interactions, RNA interactions (residues 1–33) 
and redox-dependent activities (38). Among all the well-known 
interactions of APE1 (39), nucleophosmin (NPM1) is a paradig-
matic example of how APE1 functions may be modulated by protein 
interacting partners, thus impacting tumour biology (40). As dem-
onstrated in acute myeloid leukemia (AML), cells expressing a nu-
cleolar deficient form of the NPM1 protein (i.e. NPM1c+) have an 
altered APE1–NPM1 functional interaction with consequential BER 
impairment (40,41). This finding supports the hypothesis that an al-
teration of APE1 interactions may be causally involved in cancer de-
velopment and chemoresistance. Moreover, the N-terminal region of 
APE1 is also subjected to different post-translational modifications 
(PTMs) (42). Although its functional relevance is still controversial, 
the most well-known PTM of APE1 is the cleavage of the first 33 
amino acids. This truncated protein lacks the nuclear localisation 
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signal sequence, leading to the accumulation of protein within the 
cytoplasmic compartment, and impairing the ability of the protein 
to interact with its canonical protein partners, including NPM1. 
Moreover, it has been clearly shown how the removal of the first 
33 amino acids does not affect the APE1 binding affinity for the 
abasic site, but, in contrast, increases the enzymatic catalysis when 
compared with the full-length protein (38,43,44). Up to now, the 
protease responsible for the cleavage is still unknown, even though 
it has been suggested that a Granzyme-like factor could play a role 
(45). Beyond the N-terminal cleavage, a well-known in vitro and in 
vivo PTM of APE1 is represented by acetylation. Different lysine 
residues, including the lysine 27–35 (K27–K35) cluster could be sub-
jected to acetylation (46). In acetylated (acAPE1), the positive charge 
of the N-tail of APE1 is neutralised, triggering a conformational 
change of the whole protein. Thus, acAPE1 is more prone to asso-
ciate with chromatin, and less prone to interact with NPM1. A de-
crease of the APE1–NPM1 interaction, as a consequence of APE1 
acetylation, determines inhibition of the APE1 accumulation within 
nucleoli (44,47) and an enhancement of its AP endonuclease activity 
due to an increase of the speed of product release upon cleavage 
(38,46,48). The observed effects of the PTMs occurring on the N-tail 
of APE1 highlight how the N-terminal region may indirectly influ-
ence the BER activity of APE1. Currently, the acetylation of APE1 is 
the main PTM of APE1 detected in vivo, as described in the subse-
quent paragraphs.
Upon AP cleavage promoted by APE1, a single-strand break 
bearing a free hydroxyl (OH) group at the 3′ end and a deoxyribose 
phosphate (dRP) at the 5′ end is generated. In this phase, BER could 
follow two alternative sub-pathways. In the classical mechanism, 
also called ‘short patch’ (SP-BER), polymerase β (Pol β) replaces the 
single missing nucleotide, adding the correct one at the 3′ end of 
the nick. Then, DNA ligase I (Lig I) or a XRCC1-Lig III complex, 
complete the repair (49). Another sub-pathway of BER exists, called 
‘long patch’ (LP-BER), in which Pol β, coordinated with polymerase 
δ (Pol δ), polymerase ε (Pol ε), and the sliding clamp proliferating 
cell nuclear antigen, synthetise a 2–12 nucleotides strand. The re-
maining flap is excised by flap endonuclease 1 (FEN1), while the nick 
is sealed by Lig I (50). Due to its elevated complexity, including the 
high number of BER factors involved as generated DNA intermedi-
ates, different hypothesis have been proposed to explain how the 
BER pathway steps may proceed in a coordinated way. Specifically, 
in the ‘passing the baton’ mechanism proposed by Tainer et al. (33), 
a coordination among all the BER factors in the passage of the DNA 
intermediates (BER baton) has been suggested. This model would 
explain how the cell works to preserve cellular stability, and protect 
it from the presence of potentially mutagenic DNA intermediates 
(51). In contrast, in the “BERosome” model, proposed in different 
studies (52,53), a fine regulation exists among all BER enzymes to 
coordinate every step of DNA repair. This coordination depends on 
several PTMs that regulate protein–protein interactions, including 
pathway cascade signaling, cellular localisation, conformational 
changes and protein stability (52,54). In this scenario, several other 
proteins, including p53 and NPM1, act as BER modulators (55,56). 
The efficiency of BER is also due to the coordinated use of additional 
scaffold proteins. Among them, the poly (ADP-ribose) polymerase 1 
assumes an important role in the regulation of BER enzymes. Recent 
reports have shown the AP lyase activity of poly(ADP-ribose) poly-
merase 1 (PARP1) (57), and the stimulating activity of PARP1 on 
APE1 endonuclease activity (58).
Since knock-out of DNA glycosylases does not increase sensitivity 
to oxidative stress or ionising radiations (59–61), the existence of a 
backup mechanism acting on damaged bases, typically recognised by 
BER proteins, has been suggested. In this context, a pathway known 
as nucleotide incision repair (NIR), acts directly on the 5′ side of 
the oxidised base by the direct action of APE1, thus ensuring the 
correct removal of the oxidised bases (62–67), which bypasses the 
action of glycosylases (Figure 1). The 3′ OH terminals, thus gener-
ated, are processed by FEN1 (68,69) and DNA polymerases. Several 
studies have reported this non-canonical APE1 activity operating in 
NIR, pointing to substrates that are efficiently processed, which in-
clude 5,6-dihydro-2′-deoxyuridine (DHU), 5,6-dihydrothymidine, 
5-hydroxy-2′-deoxyuridine (62,70), 5-hydroxy-2′-deoxycitidine 
(5OHC) (62,66,70) and alpha-2′-deoxynucleosides (αdA, αdT and 
αdC) (62,71). Notably, the majority of these damages are generated 
as a consequence of DNA exposure to ionising radiation (72–75). 
APE1 NIR activity is stimulated under significantly different experi-
mental conditions, in terms of salts, pH and structural requirements 
(62), compared with the classical BER activity. Notably, although 
the N-terminal region of APE1 is indirectly involved in the regula-
tion of BER endonuclease activity, it is essential for the NIR process 
(62). Timofeyeva et al. (63) have reported how the lysine residue at 
position 98 (K98) significantly contributes to the 5′ phosphodiester 
bond hydrolysis of the DNA substrate, but not to the dissociation of 
the enzyme from the product complex. Furthermore, an amino acid 
substitution of K98 influences the NIR activity more than the BER 
activity, demonstrating how the catalytic site active in BER and NIR 
is the same, although different conformations of APE1 are respon-
sible for the incision of unrelated lesions such as AP sites and DHU, 
which are substrates of BER and NIR, respectively (63).
A good and well-characterised example of canonical activity of 
BER in the maintenance of genomic stability is represented by its ac-
tivity at telomeres. Telomeres are composed of a repetitive non-coding 
DNA sequence that avoids the loss of genetic information, as the 
DNA polymerase is generally able to replicate the template DNA 
until its end, but only on the leading strand (76). In humans, the telo-
meric sequence is represented by repetitive “TTAGGG” hexameric 
blocks (77). Human telomeres are bound by the shelterin complex, 
which is composed of several protein partners that ensure stability 
and protection to the chromosome ends (78). The shelterin complex 
also functions to guarantee the acquisition and maintenance of G4 
folding (79). This secondary structure is preserved by the establish-
ment of Hoogsten hydrogen bonds between the G4 guanines (80). 
Because guanine is the base with the lowest redox potential, telomeres 
are hotspots for oxidative modifications with the consequential gener-
ation of 8-oxo-2′-deoxyguanosine (8-oxo-dG) (81), efficiently handled 
by the BER pathway to be removed and replaced. G4-8-oxo-dG sites 
are specifically recognised by the NEIL1 and NEIL3 glycosylases (82), 
which are able to cleave the oxidised base, leaving an abasic site that 
is then nicked by APE1 (83) (Figure 1). It has been shown that NEIL1 
and NEIL3 process 8-oxo-dG located in G4 structures formed in the 
promoter region of VEGF and c-Myc (83). Regarding 8-oxo-dG gen-
erated in G4 structures at telomeric regions, only NEIL3 seems to be 
able to efficiently cleave it and subsequently recruits the LP-BER ma-
chinery to favor repair (84). Moreover, NEIL3 also interacts with the 
TRF1 shelterin complex, and seems to play an essential role in coord-
inating the repair of oxidation damages, as demonstrated by telomere 
dysfunction observed in the absence of this glycosylase (84). Wallace 
et  al. hypothesised the possible involvement of NEIL glycosylases 
in both telomere maintenance and gene regulation (84). The abasic 
site generated by glycosylase is later handled by APE1 endonuclease, 
which is able to bind and process different types of G4, through the 
involvement of its acetylated lysine residues (i.e. K27–35 cluster) (48) 
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(Figure 1). The localisation of the abasic site in the quadruplex and the 
electrostatic interactions that mediate the contact of nucleic acids with 
APE1 then influence its activity on the lesion (48). The N-terminal 
region of APE1, and more specifically the lysine residues located in 
this region, are important for the regulation of the endonuclease ac-
tivity on G4-containing abasic sites (56). Specifically, APE1 mutants, 
which mimic the acetylation of lysine residues, display increased endo-
nuclease activity in vitro. The acetylation may therefore represent a 
dynamic mechanism to fine tune the activity of the protein at telo-
meric sites (48) (Figure 1). Cells depleted in APE1 showed reduced 
telomere length and the knock-out of APE1, in postnatal mice, re-
sulted in compromised development and growth, and increased senes-
cence (85). APE1 can also interact with the TRF2 and POT1 sheltering 
proteins, and its presence at telomeric sites is important in stabilising 
these regions (86). Moreover, the depletion of APE1 results in telo-
mere dysfunction and segregation defects in cells that employ alter-
native lengthening of telomere pathways or telomerase re-expression 
to elongate telomeres (86). These results suggest an interdependence 
between the BER machinery and telomere homeostasis.
Non-canonical roles of the BER pathway in the 
immunological response
The BER pathway, besides being the main mechanism for coping 
with DNA lesions described above, plays an essential role in the 
immunological response. It has been clearly shown that BER en-
zymes regulate the genomic rearrangement that induces the antigen-
stimulated somatic hypermutation (SHM) process, responsible for 
the diversification of the variable genomic regions of the heavy and 
light chains of immunoglobulins, and plays a central function in the 
process of class switch recombination (CSR) responsible for diversi-
fication of the heavy chain constant region (87). These two antibody 
maturation mechanisms are dependent on the activation-induced 
cytidine deaminase (AID), which converts cytosine to uracil in the 
variable (V) and switch (S) regions of the immunoglobulin gene. 
APE1, through its AP-endonuclease activity, is responsible for the 
introduction of DNA nicks when AID-dependent deaminated cyti-
dine is removed by the glycosylase, UNG2-dependent BER. Despite 
several uracil glycosylases being present in mammals, APE1 is the 
only AP-endonuclease, although a weak endonuclease activity has 
been recently identified for APE2 (88–90). Besides APE1 and UNG2, 
all the other BER enzymes have been found to participate in the 
uracil removal process (91). Their role in SHM and CSR strongly de-
pends on crosstalk between each protein partner, and is finely tuned 
by the expression levels of each partner and by specific regulated 
posttranslational modifications, such as phosphorylation of Ser38 
in the AID protein (92,93). In particular, while APE1 endonuclease 
activity is important for CSR, it has been shown to be dispensable 
for SHM- and AID-induced DNA breaks. In fact, APE1 does not 
contribute to DNA cleavage through processing of AP sites, but 
Figure 1. BER pathway and the ‘Deathly Allows’. Representational cartoon of canonical and non-canonical functions of enzymes belonging to the BER pathway. In 
the middle, canonical BER is represented as starting by the action of several glycosylases on non-bulky lesions (8-oxo-dG). When the abasic site (F) is generated, 
APE1 cleaves it, generating a single-strand break that can be processed by a short- (SP-BER) and long- (LP-BER) patch. Several BER enzymes are also involved 
in other important cellular pathways regarding DNA processing (left blue side), including a NIR pathway, telomere maintenance and transcriptional regulation. 
Recently, new discoveries regarding a role of BER enzymes in RNA processing (right red side) are emerging, including mRNA and miRNA processing and/or 
decay. Moreover, BER enzymes are also involved in the processing of DNA:RNA hybrids, including 8-oxo-G and ribose monophosphate abasic site embedded in 
DNA (top). Finally, their extracellular secretion has been also recently hypothesised (bottom). See the text for further information. Figure available in colour online.
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rather, it may function as a DNA end-processing enzyme to facilitate 
the joining of broken ends during CSR (94,95). APE1 endonuclease 
activity is likely to remove 3′-tyrosyl residues from the DNA end 
after topoisomerase 1 (Top1) cleavage and Top1-cc degradation, 
which is essential to efficient recombination of broken S regions. 
Additionally, S regions are subjected to a high rate of transcription 
driven by cytokine-inducible promoters, which regulate the CSR 
process. Moreover, because APE1 is dispensable for AID activity, 
understanding the mechanism by which AID is targeted to its sub-
strates is of great interest, given the potentially deleterious conse-
quences of AID’s mutagenic activity (96). While the endonuclease 
activity of APE1 in the CSR process is well-established, its contri-
bution as a transcriptional coactivator has been only hypothesised. 
In fact, the remaining CSR activity observed in APE1-endonuclease 
activity deficient cells (88) could be explained by the ability of APE1 
to stimulate the DNA-binding activity of several transcription fac-
tors, including nuclear factor kappa B (NF-κB) and a few others, 
involved in inflammation and immunological responses (6,97,98). 
Very recently, using different APE1 inhibitors and APE1 DNA-repair 
and redox-defective mutants, we provided more evidence in support 
of this hypothesis, demonstrating that APE1 redox function also 
plays an important role in regulating CSR through the IL-6 signaling 
pathway and proper IgA expression (99).
The role of the BER pathway in trascriptional 
regulation
A growing list of BER proteins, that were initially thought to exclu-
sively function in DNA repair, are emerging as important in tran-
scription (100). It is perhaps not surprising that these two processes 
are often coupled, when considering the mutagenic potential of the 
transcriptional process. DNA lesion repair, in transcriptionally active 
genes, must be kept under strict control to maintain transcriptional 
fidelity and genome stability. However, it does not simply involve a 
preferential repair of the transcribed DNA strand but, as suggested 
by several findings, a more physically and functionally intertwined 
crosstalk between the two processes must exist. Importantly, re-
cent studies have generated a substantial body of evidence pointing 
to a direct function of DNA repair enzymes as coactivators of 
transcription.
APE1 represents a paradigmatic example of a DNA repair en-
zyme with a peculiar function as a transcriptional regulator. Indeed, 
APE1 plays a role in the regulation of expression of human genes in 
response to oxidative stress conditions by stimulating the DNA 
binding activity of several transcription factors, such as nuclear 
factor kappa B (NF-κB), Egr-1, Hif-1α, Nrf1 and STAT3, thus 
influencing the onset of inflammatory and metastatic processes (97) 
(Figure 1). Recently, a direct role of APE1 has also been character-
ised in the transcription of sirtuin 1 (SIRT1) gene, by binding to 
negative calcium responsive element (nCaRE) sequences present on 
its promoter demonstrating that BER-mediated DNA repair pro-
motes the initiation of transcription of the SIRT1 gene upon oxida-
tive DNA damage (98) (Figure 1). Paradoxically, it has been shown 
that programmed DNA single or double strand breaks, with con-
comitant activation of the DNA damage response, can induce tran-
scription at gene promoters (101,102). Conventionally, DNA 
modifications (especially oxidation) are widely thought to be 
harmful for cell stability (103). The only described exceptions, rela-
tive to DNA modifications with important regulatory roles, are 
5-methylcytosine and uracil, which are enzymatically generated in 
DNA under controlled conditions to fulfil crucial regulatory 
functions as epigenetic marks, or to be involved in antibody diversi-
fication (104). The existence of modifications with potential regula-
tory functions on other bases remains to be investigated. Oxidative 
DNA modification, as a consequence of the exposure to reactive 
oxygen species, is very frequent and guanine is the most susceptible 
targeted base, with 8-oxo-dG as the most common product (105). 
The distribution of 8-oxo-dG sites is not random throughout the 
genome, but occurs more frequently at the promoter region of active 
genes, thus contributing to transcriptional regulation (106). If not 
repaired, 8-oxo-dG is moderately mutagenic, causing a G to T 
transversion mutation that is thought to be responsible for initiating 
and driving carcinogenesis and neurodegenerative diseases, such as 
Alzheimer’s and Parkinson’s diseases (107–109). Recent evidence 
has highlighted how the repair of 8-oxo-dG by OGG1 is involved in 
the regulation of transcription, through the action of specific tran-
scription factors, and also in signal transduction. Numerous reports 
have reported an interplay between DNA repair of 8-oxo-dG and 
transcription activation, mostly when this modification is found in 
promoter regions (98,101,110). These studies proposed that the 
8-oxo-dG BER-mediated repair may serve as a modulator for tran-
scription efficiency, supporting a growing body of evidence regarding 
the role of 8-oxo-dG as an epigenetic-like DNA modification 
(102,111). The long-standing view has been that 8-oxo-dG is muta-
genic and can negatively impact cellular processes such as transcrip-
tion. When 8-oxo-dG is present in the template strand, it can slightly 
inhibit the advancement of RNA polymerase II (112), and the initi-
ation of 8-oxo-dG repair may cause polymerases to stop (113); fur-
thermore, the presence of 8-oxo-dG in transcription binding sites 
can negatively affect the transcription factor binding activity (114–
116). For all these reasons, it is thought that 8-oxo-dG may act as a 
negative signal for transcription. However, there are a few notable 
findings showing that 8-oxo-dG, when recognised by OGG1, pro-
vides a platform for the coordination of the initial steps of the BER 
pathway repair coupled with the assembly of the transcriptional ma-
chinery to prompt the expression of redox-regulated genes. In par-
ticular, the presence of 8-oxo-dG in promoters can increase gene 
transcription via the BER pathway; these are well-documented cases 
of the BCL2 apoptosis regulator (B-cell lymphoma 2) (117), SIRT1 
(98), vascular endothelial growth factor (VEGF) (118,119) and tu-
mour necrosis factor-alpha (TNFα) (110) gene expression. We previ-
ously proposed that BER-mediated repair of an oxidised guanines at 
nCaRE sequences is a key event for SIRT1 transcription (98). We 
hypothesised that the nick, introduced by APE1 during DNA repair, 
might favor local topological relaxation, facilitating the recruitment 
of RNA polymerase for gene transcriptional activation. A  similar 
mechanism of transcriptional activation was described later by 
Pastukh et  al. (118), in the context of the VEGF gene, and by 
Boldogh et  al., who demonstrated OGG1 recruitment and 
upregulation of proinflammatory genes upon TNFα-induced oxida-
tion of G in NF-κB consensus sequences (110,120). Of note, this re-
ported role of 8-oxo-dG and OGG1 in the activation of inflammatory 
genes could explain the documented immune deficiencies observed 
in OGG1−/− mice (121,122). Furthermore, using 8-oxo-dG site-
specifically synthesised reporters of the VEGF regulatory sequence, 
Burrows and co-workers have further characterised the mechanism 
of coupling BER and transcriptional activation. In particular, they 
suggested that the presence of 8-oxo-dG in DNA could provide a 
gene for up/down regulation depending on the strand context. 
Specifically, they demonstrated that the activation of VEGF tran-
scription depended on the oxidation of Gs present in the guanine-
rich potential G-quadruplex (G4)–forming sequence (PSQ). Their 
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model proposed that when 8-oxo-dG is present in the coding strand 
of the VEGF PSQ promoter, the produced AP site favors the pro-
longed stalling of APE1, leading to its inability to cleave in the G4 
context but allowing the recruitment of the transcriptional activating 
machinery for gene induction. In contrast, the presence of 8-oxo-dG 
on the template strand activates the transcription-coupled nucleotide 
excision repair pathway, which attenuates transcription (101,119). 
Very recently, the same group reported a similar mechanism of ac-
tion for the G-rich potential Z-DNA forming sequences (PZS) (123). 
This concept has also been shown for other promoters such as that 
of the endonuclease III-like protein 1 (NTHL1) (101), RAD17 (124), 
proliferating cell nuclear antigen (PCNA) (125) and NEIL3 (126), 
which expanded the generalisation of this model mechanism and 
emphasised the importance of G4-fold oxidation as a critical driver 
for gene activation. Secondary structures are key elements in the 
regulation of transcription, because the frequency of potential G4 
forming sequences within gene promoters is 1.8-fold higher if com-
pared with other randomly considered regions (127). In addition, the 
GC-content positively correlates with transcriptional activity of 
genes (128), further supporting the possibility that oxidation of G 
and BER activities have the potential to trigger gene expression. 
However, the selective induction of 8-oxo-dG in promoter sequences, 
described in the abovementioned studies, appears difficult to explain 
as a consequence of general oxidative stress. Perillo et al. (117) sug-
gested an intriguing hypothesis involving a possible alternative ex-
planation for the generation of oxidised bases localised in promoter 
regions. They showed that lysine specific histone demethylase (LSD1) 
accounted for the generation of 8-oxo-dG in the estrogen-responsive 
promoter region of the bcl-2 gene. By an oxidative process that re-
leases H2O2, LSD1 promotes the demethylation of histone H3 at ly-
sine 9, which, in turn, modifies the surrounding DNA and determines 
the recruitment of OGG1 and topoisomerase IIb to remove damaged 
DNA bases (129). Finally, another mechanism postulates a specific 
role for the excision of 8-oxo-dG. Boldogh et al. (130) showed that 
a stoichiometric complex of OGG1 with its excised substrate modi-
fication had a high binding affinity for small GTPases, such as Ras, 
Rac1 and Rho, and that this binding acted as a guanine exchange 
factor (GEF), consequently activating downstream cellular signaling. 
Together, these interesting results highlight an intertwined role be-
tween DNA repair and gene transcription, which is a phenomenon 
gaining more interest. Furthermore, coupling BER with transcrip-
tional activation leads to the hypothesis that oxidative modification 
of G to 8-oxo-dG may have regulatory and possibly epigenetic-like 
features in cells. G4-forming sequences can especially sense oxidative 
stress and lead to repression or enhancement of transcription. 
However, whether 8-oxo-dG is an epigenetic modification is not 
clear and needs further discussion. Typically, epigenetic marks com-
prise DNA methylation, histone modification and nucleosome local-
isation, all of which are products of the activity of specific enzymes 
that modulate the access of transcription machinery. Conversely, 
DNA oxidation is efficiently repaired by BER and therefore has 
never been considered epigenetic, especially because it lacks the her-
itability from mother to daughter as established for the epigenetic 
definition. Furthermore, the toxic aspect of 8-oxo-dG cannot be ig-
nored. Therefore, further studies are needed to establish whether this 
modification can be considered helpful, by facilitating gene expres-
sion, or as a process leading to mutagenic potential. It can probably 
be argued that deviations from the proper response to oxidative 
stress may be due to the impaired action of BER at oxidised guanines, 
which in turn might be the etiological link of 8-oxo-dG to several 
pathologies. This consideration also opens new scenarios to 
pharmacologically modulate OGG1 and APE1 activity to prevent 
degenerative diseases associated with oxidative stress, which can be 
derived by an inaccurate action of the two proteins at oxidised 
guanines.
The roles of the BER pathway in RNA 
processing
In the past few years, a clear picture of the involvement of DNA 
repair enzymes in specific aspects of RNA metabolism has emerged. 
In particular, a large cohort of BER enzymes has been implicated 
in RNA processes, especially linked with quality control towards 
damaged (i.e. abasic and oxidised) RNA molecules (131–133). BER 
enzymes typically cope with oxidative modifications occurring on 
DNA, but increasing evidence has suggested the involvement of the 
BER pathway as the mechanism of surveillance needed to remove 
damaged RNA molecules to ensure cell viability (133). Currently, 
an unequivocal description of how cells may deal with oxidised 
RNA is still missing. Notably, no known enzyme seems to be de-
voted to the recognition and removal of abasic or oxidised RNA. 
However, a quality control mechanism should exist to protect from 
the negative consequences of unrepaired RNA damage, which could 
lead to an impairment of protein synthesis and noncoding RNA 
expression, with deleterious effects on the fate of cells. Therefore, 
a productive crosstalk between DNA repair enzymes and proteins 
associated with the RNA processing machinery seems more than 
reasonable. In this context, among the BER components, APE1 has 
been the particular focus of attention. Increasing evidence has re-
inforced the view, suggested by our studies of a role of APE1 as a 
‘cleansing’ factor for damaged oxidised/abasic RNA, and possibly 
highlighted its unsuspected function in RNA metabolism, thus af-
fecting gene expression (5,133,134) (Figure 1). Initially, the poten-
tial involvement of APE1 in RNA biology was mainly based on in 
vitro findings. In particular, we and others reported that APE1 bound 
structured RNA molecules (135), cleaved abasic single-stranded 
RNA (ssRNA), and was involved in RNA-decay, with 3′-RNA 
phosphatase and 3′-exoribonuclease activities (136). In parallel 
studies, as the interactome of APE1 has been shown, APE1 inter-
action with components of the RNA metabolism machinery defini-
tively proved the significance of APE1’s role in RNA metabolism in 
vivo (6,39). Proteomic analyses from our studies showed that the 
APE1 interactome was mostly comprised of proteins involved in 
ribosome assembly, regulation of mRNA stability (e.g. HNRNPK, 
YB-1, NPM1 and PABPC1), RNA splicing (e.g. PRPF19, SNRPB 
and SRPK1) and ribonucleoprotein complex biogenesis (e.g. RPL11, 
DDX6 and RPS14) (6). In support of these observations, we recently 
also showed that APE1 may represent a new hub in RNA-processing, 
including effects on ncRNAs such as miRNAs (6) (Figure 1). This is 
consistent with recent studies showing that the cellular response to 
damage requires not only protein-coding genes, but also a subset of 
ncRNAs (14,137,138). In fact, activation of DNA damage induces 
the expression of multiple kinds of ncRNAs, such as miRNAs and 
the recently discovered DROSHA- and Dicer-dependent RNA, the 
DSB-induced small RNAs and the long intragenic non-coding RNAs 
(lncRNAs), which contribute to the fine tuning of damage repair to 
ensure DNA integrity (4). Numerous studies reported that ncRNAs, 
in particular miRNAs, were able to regulate the DDR by acting on 
several sensors of damage (e.g. γ-H2AX), as well as on crucial signal 
transducers (e.g. ATM, ATR and DNA-PKcs.) and effectors (CHK1, 
p53 and p21) (137). However, a bidirectional regulatory pathway 
exists between ncRNAs and DDR factors. It has been postulated that 
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few DDR proteins modulate miRNA post-transcriptional processing 
by regulating the essential steps of their processing and maturation 
(6,137). Remarkably, in this context, we recently showed a role for 
APE1 in pri-miRNA processing and stability via association with the 
DROSHA-processing complex during genotoxic stress. We showed 
that APE1 endonuclease activity was required for the processing of 
miR-221/222 in regulating the expression of the tumour suppressor 
phosphatase and tensin homolog (PTEN). These results highlight 
how APE1 regulates gene expression through its direct binding and/
or processing of specific miRNAs contributing to cancer progression 
(6). It is still unknown whether this mechanism is also involved in 
chemoresistance in cancer. The majority of studies on ncRNAs in 
the DNA damage field have so far focused on the role of miRNAs, 
although a role for lncRNAs has also been reported. They have been 
described to be induced upon DNA damage and associated with 
ribonucleoproteins and proteins in chromatin by acting in various 
ways, including as signals, as decoys, or as scaffolds for these protein 
complexes leading to the regulation of DDR genes (137,139). At 
present, nothing is known about a possible interaction between 
lncRNAs and BER enzymes; however, because the expression of 
lncRNAs has emerged as a new topic in DNA damage, this relation-
ship cannot be excluded. Preliminary results from our laboratory 
identified few lncRNAs bound by APE1, which might function to-
gether with APE1 in DNA repair and safeguarding genome integrity 
(G. Antoniali et al., in preparation). In accordance with a new role 
for APE1 in RNA described so far, depletion of this protein in tu-
mour cells leads to nucleolar defects (140), accumulation of oxidised 
RNA species as well as pri-miRNAs (6,56), alteration of miRNAs 
expression, impaired protein synthesis and reduced cell growth (56). 
All these findings, together with the cytoplasmic accumulation of 
APE1 in several tumour cell types (141), support a major function 
of APE1 in RNA-processing/decay. Taking into account these obser-
vations, the importance of a better understanding of the role played 
by the BER enzymes in RNA-related processes becomes essential, 
especially when considering that some pathologies, including neuro-
logical disorders and cancer, are associated with deficiencies to both 
RNA processing and DNA repair (142). Furthermore, these insights 
might also explain the complexity that underlies BER involvement in 
the onset of chemoresistance. In conclusion, further studies unveiling 
the regulatory mechanisms coordinating the interplay between BER 
activity and RNA processing will be necessary to understand the 
complexity of DNA repair programs and, finally, these notions can 
definitively facilitate the development of new anticancer agents.
The BER pathway as a new player in RNA:DNA 
hybrid processing
RNA:DNA hybrids physiologically occur during DNA replication 
and transcription, telomere elongation, retroviral infection and 
retro-element mobilisation (143). In eukaryotic cells, RNA:DNA 
structures are classified in: (i) a configuration in which ssRNA is 
paired to ssDNA; (ii) a R-loop structure, in which a single DNA 
strand, belonging to the duplex DNA molecule, is hybridised with 
ssRNA and finally (iii) an incorporation of a single, or more, 
ribonucleotide(s) (rNMPs) in genomic DNA (144). Although 
RNA:DNA hybrids are needed for the successful ending of cellular 
processes, their persistent presence can induce harmful consequences 
to genome integrity causing replication fork arrest with replication–
transcription collision and chromosomal breakage repair (145,146). 
For these reasons, a family of endoribonucleases, called RNase H, 
process the RNA:DNA hybrids to restore regular genomic stability. 
Currently, in-depth studies regarding the incorporation of rNMPs 
within the DNA have been reported (147). This particular RNA:DNA 
hybrid structure is one of the most common types of DNA damage 
because of its high frequency and abundance in the genome of both 
prokaryotes and eukaryotes (148–151). Different methodologies are 
under development for the detection of ribonucleotides incorporated 
in DNA (152–155), but the development of different sophisticated 
high-throughput sequencing-based approaches (156), including 
ribose-seq (149,157), hydrolytic end-sequencing (HydEn-seq) (158), 
polymerase usage sequencing (PU-seq) (159), embedded ribose-
sequencing (emRibo-seq) (160) and (trimethylsilyl)diazomethane 
derivatisation followed by liquid chromatography–tandem mass 
spectrometry (154) analyses have facilitated the discovery of distri-
butions and abundances of rNMPs in genomic DNA. Remarkably, a 
widespread but nonrandom distribution of rNMPs presenting sev-
eral hotspots and a preference for rCMPs and rGMPs has been dis-
covered (149). The high frequency (>100 million in mammalian 
cells) of rNMPs included in the nascent DNA molecule found during 
each replication cycle and DNA repair could have different origins. 
An imbalance of the rNTPs:dNTPs ratio, generally in favour of 
rNTPs in normal conditions (149,161), and an imprecise 
discriminating capacity of DNA polymerases, which can erroneously 
incorporate rNTPs rather than dNTPs, are two aspects playing a role 
in these mechanisms (162–166). Moreover, RNA primers, synthetised 
to allow DNA lagging strand replication (167), could be considered 
an additional cause of the presence of rNMPs in DNA. Indeed, if 
RNA primers are not correctly removed, isolated rNMP(s) can be 
included among consecutive Okazaki fragments, which could then 
permanently persist within genomic DNA (168). The biological rele-
vance of rNMP incorporation in genomic DNA is emerging from a 
growing body of recent scientific studies. Whatever the cause of the 
rNMP(s) incorporation, the additional 2′-OH group on one or more 
rNMP(s) alters DNA elasticity and structure in a sequence-dependent 
manner, destabilising the DNA backbone, increasing the suscepti-
bility to DNA hydrolysis, and finally causing strand cleavage and/or 
mutability (148,169–174). The genomic DNA stability, perturbed by 
the rNMP(s) presence, is preserved by the combined action of several 
enzymes orchestrated in a unique pathway called ribonucleotide ex-
cision repair (RER) (160). One of the most important RER enzymes 
is RNase H2 (175), an endonuclease involved in the cleavage of the 
phosphodiester bond at the 5′ side of a single, or more allocated in 
series, rNMP(s) embedded in DNA. Similar to BER, FEN1 incises the 
3′ side of the partially excised rNMP to definitely release it from the 
genomic DNA, leaving a nick that will be finally repaired by Pol δ, 
Pol ε and Lig I enzymes (175,176). The missing processing of rNMPs 
embedded in DNA results in embryonic lethality in mice (160,177), 
as a consequence of activation of a p53-dependent damage response 
(178), cell cycle arrest and blockage of DNA replication (179,180). 
Moreover, it has been documented how mutations in each of the 
three RNase H2 subunits are correlated with the onset of the Aicardi 
Goutières syndrome (AGS), an inflammatory disorder (181,182) 
whose effects are mainly associated with increased levels of rNMP(s) 
incorporated in genomic DNA, that partially stimulates the activa-
tion of the innate immune response by IFNγ signaling and DDR 
(160,180,183,184). Notably, a recent work performed on mice, ex-
pressing different types of AGS-mutated RNase H2, has demon-
strated the existence of a threshold in rNMPs levels during embryonic 
development. When the level is moderate, an activation of the cGAS–
Sting DNA sensing innate immune response leading to perinatal le-
thality was observed. When a high abundance of rNMPs exceeded 
the threshold, the subsequent activation of p53-dependent DNA 
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damage caused early embryonic lethality (185). Importantly, a rela-
tionship between RNase H2 and rNMPs incorporation with cancer 
is emerging. Screening of a cohort of patients with gastric cancers 
has recently revealed an association between the onset of gastric 
cancer and mutations in gene coding for the subunit B of RNase H2 
(186). In parallel, a recent study has shown that RNase H2 can be 
also considered as a colorectal tumour suppressor gene (187). 
Furthermore, loss of RNase H2, in the murine epidermis, results in 
spontaneous DNA damage and development of squamous cell car-
cinoma (188). In light of this, it becomes clear how additional inves-
tigations are needed for clarifying the association between mutated 
RNase H2 and/or rNMP(s) DNA-incorporated and pathology. 
Although the deleterious effects of rNMP(s) incorporations in DNA 
are well-known, a new hypothesis has been suggested involving a 
putative helpful role for rNMP(s). Specifically, it has been shown 
that more rNMPs, consecutively incorporated in yeast genomic 
DNA, may mark the nascent DNA strand, initiating programmed 
mating-type switching (189). Furthermore, a recent study reported 
how the erroneous ability of polymerase µ (Pol µ) to discriminate 
rNMPs during the NHEJ pathway (190–192) could be detrimental, 
as well as advantageous, for the cell. Indeed, by inserting rNMPs 
with a higher base fidelity compared with dNMPs (192), Pol µ might 
stimulate Lig IV in promoting initiation of the NHEJ mechanism 
(193). In parallel, another interesting observation has linked the ac-
tivity of RNase H2 with the mis-match repair (MMR) pathway 
(164,194). The rNMP cleavage mediated by RNase H2 works as a 
signal for MMR enzymes, which are then stimulated to process the 
mismatched sites located in the surroundings. Finally, although the 
results show that rNMP in DNA induced a decrease of DNA poly-
merases processivity (195), the choice of which rNMP is embedded 
in the template strand can influence the DNA synthesis (195–197). 
A still unanswered question is whether alternative DNA repair sys-
tems, other than the RER pathway, may remove rNMPs embedded 
in DNA (147,198,199). Until now, topoisomerase I  (Top1) is the 
only enzyme able to cleave rNMPs embedded in DNA, when the 
RER pathway is not working. Top1 is an essential enzyme thought 
to resolve DNA supercoils generated during replication and tran-
scription (200,201). It has been shown that Top1, cleaving at the 
5′-side of rNMPs (199,202) and generating 5′-OH and 3′-cyclic 2′-3′ 
phosphate as DNA termini, is able to compensate for RNase H2 de-
ficiency, although it causes high levels of DNA mutations (199,203). 
Later, the cleavage is followed by nick processing by Srs2-Exo1 
(204,205). A recent analysis of yeast has identified a role of Apn2 
(homologous to human APE1) in restoring the genome integrity per-
turbed by the Top1-catalysed rNMPs cleavage by resolving 3′-end 
blocks generated by Top1 (206). Recently, Zimmermann et al. (207) 
have shown how the cleavage of rNMPs by Top1 results in the for-
mation of PARP-trapping lesions that impede DNA replication. In 
contrast, studies performed on the MMR and the nucleotide excision 
repair (NER) pathways have shown the inefficiency of these path-
ways in the processing of this particular lesion (199,208). The NER 
pathway generally excises bulky and non-bulky DNA base adducts 
(209). Because rNMP incorporation distorts the DNA backbone, 
NER enzymes could be good candidates in repairing this type of 
damage. Data obtained from Bacteria showed an involvement of 
NER factors in the removal of rNMPs in the DNA (210,211), in 
contrast to what is observed for human NER factors, which are not 
involved in rNMP repair (208). Evidence about this difference has 
not improved, but may suggest that NER factors might have lost this 
function during evolution. In contrast, data collected in vitro have 
shown that the MMR mechanism can target mismatches with 
rNMPs both in Escherichia coli and Saccharomyces cerevisiae gen-
omic DNA (197). Increasing knowledge in this field represents an 
important goal in the DNA repair and in the pathogenesis associated 
with this type of damage. For this reason, we improved the study of 
DNA repair mechanisms acting on rNMPs embedded in DNA, 
under conditions in which RER is functionally inactive. In our la-
boratory, while studying a putative role of BER in the removal of 
rNMPs embedded in the DNA, we discovered that BER was not ac-
tive on this type of lesion (7). In this context, several published re-
ports have hypothesised that, among the many millions of rNMPs 
that are introduced into the mammalian genome per cell cycle (198), 
damaged rNMPs (such as the ribose monophosphate abasic site and 
oxidation) can also be incorporated into DNA. In fact, RNA mol-
ecules, as well as rNMPs present in the nucleotide pool, are also 
susceptible to oxidative insults (108,212). Although not fully ex-
plored, the generation of hydroxyl radicals from oxidative stress 
could be the cause of the conversion of the deoxyribose sugar into 
ribose in vitro and in vivo (212). This can happen both in the cellular 
nucleotide pool and directly into the DNA. Additional data are 
needed to support this hypothesis. Moreover, a significant generation 
of abasic sites has been demonstrated upon RNA oxidation and al-
kylation (23). For these reasons, whereas the role of the RNase 
H2-initiated RER mechanism of DNA repair in recognising and 
cleaving rNMPs embedded in DNA is well-established (178,198), 
little is known regarding the possible involvement of the RER 
pathway, or other DNA repair pathways, in the removal of damaged 
rNMPs. Again, a role of the BER pathway was addressed in our la-
boratory. For its abilities, BER may represent one of the best candi-
dates to work on modified rNMP(s) during DNA repair. Although 
APE1, in contrast to RNase H2, does not work on rGMP embedded 
in DNA (7), it has nevertheless been demonstrated to cleave the ri-
bose monophosphate abasic site incorporated in the DNA (Figure 1). 
In contrast with expectations, RNase H2 does not work on this dam-
aged base, confirming an APE1-exclusive function. Additionally, we 
focused on the 8-oxo-guanosine (8-oxo-G)-modified base. First, we 
found an inability of human RNase H2 in recognising and cleaving 
this modified rNMP embedded in DNA. We then studied the BER 
pathway, in which one of the most known bifunctional glycosylases, 
active in processing the 8-oxo-dG and FapyG DNA lesions, is OGG1 
(213,214). Although OGG1 also interacts with undamaged G, it is 
specific enough to discriminate and not to process it (215). In our 
recent report (7), we found that OGG1 was able to recognise and 
bind the 8-oxo-G embedded in DNA, as efficiently as its canonical 
substrate (8-oxo-dG) (Figure 1). Moreover, when co-incubated with 
APE1, it showed no glycosylase activity, being unable to process the 
8-oxo-G and to generate a substrate suitable for APE1. Notably, we 
discovered and characterised the NIR activity of APE1 on the 
8-oxo-G substrate. APE1, although weakly, was able to cleave 
8-oxo-G using experimental conditions specific for NIR. 
Furthermore, as observed during canonical NIR activity, APE1 
works as an 3′-exonuclease on the newly generated 3′-OH terminus 
(Figure 1). We recently improved our knowledge in this topic by 
discovering that, although human and Archeal RNase H2/II proteins 
are not able to process the 8-oxo-G or the ribose monophosphate 
abasic sites embedded in DNA, they were able to bind these dam-
aged bases. In contrast, we found that E.coli RNase HII possessed a 
high enzymatic activity on both the 8-oxo-G and ribose 
monophosphate abasic containing substrates, suggesting a loss of 
function during phylogenetic evolution (216). Recently, it has been 
found that rNMP(s) is also incorporated by DNA polymerase γ in 
mitochondrial DNA (mtDNA), in heavy as well as light strand DNA. 
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Increased levels of embedded ribonucleotides, affecting mtDNA sta-
bility and impairing new rounds of mtDNA replication, may con-
tribute to new pathogenic mechanisms (217–220). A  recent work 
conducted on yeast has demonstrated that a repair mechanism for 
rNMPs mis-incorporated is lacking (221). Further studies are needed 
regarding the consequences of rNMP incorporation in mtDNA and 
its repair processing.
BER enzyme signatures in cancer
Because of the involvement of the BER pathway in cancer and be-
cause of evidence regarding BER factor secretion (see paragraph 
below), extensive efforts have been directed to evaluate the prog-
nostic and predictive tumour biomarker potential of BER enzymes 
(222) (Figure 2). Several studies described the alterations of the 
APE1 genetic sequence, expression and distribution in several tu-
mours (223). In different types of solid tumours, an increased APE1 
expression is associated with lower survival rates and, at the same 
time, an aberrant nuclear and cytoplasmic localisation of APE1 is a 
sign of poor outcome (224). A study performed on a cohort of pa-
tients with gallbladder cancer showed that high expression of APE1 
protein was positively correlated with tumour stage and positive 
lymph node status; in contrast, no association with tumour differ-
entiation and metastatic condition was detected (225). It should be 
noted that not only the protein level, but also the subcellular local-
isation of APE1 was altered. APE1 displayed a nucleo-cytoplasmic 
localisation, especially in patients in which a higher level of protein 
was detected (225). Regarding hepatocellular carcinoma (HCC), an 
upregulation of APE1 occurred at the transcriptional level, which 
was linked with the progression of the disease (226). Moreover, fur-
ther studies showed an enhanced APE1 protein expression in tumour 
tissue compared with healthy controls (227). Immunostaining ana-
lysis revealed elevated levels of APE1 in pancreatic adenocarcinoma 
tissue (228), and also in prostate, esophageal, gastric, salivary gland 
carcinomas (229–232) and non-small-cell lung cancers (233). In all 
cases, this feature correlated with a lower survival of patients (231–
233). Furthermore, in tumour tissues derived from ovarian cancer, 
several studies highlighted an altered overexpression and localisa-
tion of APE1 (234,235). However, in different cohorts of ovarian 
cancer, there were conflicting studies regarding the correlation be-
tween the subcellular localisation of APE1 and cancer outcomes 
(223). In colorectal cancer (CRC), increased APE1 levels and cyto-
plasmic localisation in tumour tissue and colon cancer stem cells have 
been observed (236,237); furthermore, the APE1 overexpression 
Figure 2. Overview of the most common BER-related alterations and relevance as potential molecular biomarkers in cancer. Symbolic illustrations of organs are 
shown, in which the main alterations of BER enzymes or BER-related alterations are listed into the connected colored boxes. See the text for further information. 
Figure available in colour online.
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in liver metastasis has been correlated with poor prognoses (238). 
Concerning breast cancer, conflicting data are available. Some ana-
lyses reported that APE1 expression was higher in patients with 
triple negative breast cancer (TNBC), which was associated with 
tumour size (239), while another study reported that a decreased 
APE1 level was linked to aggressive histological features and triple 
negative phenotypes (240). Similarly, loss of APE1 expression and 
poor prognoses were found in glioma compared with normal brain 
tissue (241); however, an increase in the APE1 protein was observed 
in post-treatment glioblastoma tumours (242). Along with the ex-
pression level of APE1, its acetylated status has also been considered 
because it modulates APE1 activity. In particular, elevated levels of 
acAPE1 in colon, lung and pancreatic cancer tissues, leading to an 
increased AP-endonuclease activity, have suggested the occurrence of 
a compensatory mechanism in response to genotoxic stress induced 
by chemotherapy to maintain tumour cell proliferation capacity 
(243). Decreased APE1 acetylation status was associated with TNBC 
(244), demonstrating how PTMs occurring on APE1 is related to 
cancer development (244). Finally, a transcriptome analysis revealed 
an increased expression of APE1 and other genes of its interactome 
in the lymphocyte T cells of childhood acute lymphoblastic leu-
kemia (245). Notably, correlation analyses were performed to link 
the overexpression of APE1 and the levels of its interacting pro-
teins. For example, a cytoplasmic overexpression of APE1 and of its 
interacting protein, NPM1, were found in different studies, such as 
in a cohort of patients with ovarian cancer (246) with serous ovarian 
adenocarcinomas (247), indicating an association with lymph node 
metastasis, chemoresistance and an overall poor prognosis. Another 
positive correlation was observed between retinoic acid nuclear re-
ceptor (RARα) and APE1 in patients with multiple myeloma (248). 
Indeed, the binding of RARα to its DNA response elements (RARE) 
is dependent on the redox function of APE1 (249). However, an 
inverse association has been found between APE1 and the tumour 
suppressor, PTEN, in glioblastoma, colorectal, breast, cervical and 
non-small cell lung cancers (6). Notably, high levels of PTEN and 
low levels of APE1 mRNA expression were associated with better 
prognoses in human melanomas (250). Furthermore, not only pro-
teins but also miRNAs have been shown to be correlated with APE1 
in tumours. Indeed, a negative correlation was found between miR-
765 and APE1 expression in osteosarcoma patients. Specifically, a 
higher expression of miR-765 was associated with decreased APE1 
and good survival in response to cisplatin treatment (251). In add-
ition, the downregulation of miR-513-5p was found in patients with 
osteosarcoma. The decreased level of miR-513-5p has been correl-
ated with APE1 overexpression and radioresistance (252). Finally, 
an inverse correlation between APE1 and miR/priR-miR-221/222 
expression was found in a cohort of human cancer specimens, such 
as glioblastoma, colorectal, breast, cervical and non-small cell lung 
cancers (6). In this context, the possibility to create a screening panel 
of the biomarker interactomes, involved in tumour development, 
should be carefully evaluated.
The expressions of other BER enzymes have been evaluated in 
the literature as potential biomarkers. For instance, OGG1 is esti-
mated to be a prognostic biomarker of CRC patients survival; and 
low levels of OGG1 mRNA in marginal colon tissue were associated 
with longer survival in CRC patients following therapeutic surgery 
(253). Furthermore, low mRNA and protein levels of SMUG1 were 
associated with adverse clinic-pathological features in breast cancer 
patients (254). Regarding CRC, an overexpression of N-methylpurine 
DNA glycosylase (MPG), OGG1, APE1, Pol β, PARP1 and XRCC1 
was also shown to be linked with poor pathological outcomes 
(222,255); only the overexpression of MPG and Pol β, and not of 
XRCC1, were positively correlated with higher rates of tumour pro-
liferation when each individual CRC case was taken into account 
(222). Moreover, an increased expression of Pol β was also ob-
served in gastric, uterine, prostate, ovarian and thyroid carcinomas 
(256). Limited to Pol β, overexpression was also consistently asso-
ciated with tumour stage of gallbladder cancer (225). Furthermore, 
a cancer-related isoform of PCNA has been specifically detected 
in prostate and breast cancer (257,258). Moreover, a positive cor-
relation between the upregulation of FEN1 and aggressiveness in 
breast cancer patients has been observed (259). FEN1 has been also 
found overexpressed in testis, lung and brain tumours (260). In the 
case of XRCC1, its overexpression, in lung and liver-cancer patients, 
was associated with low expression of aldehyde dehydrogenase 2 
(ALDH2), resulting in a poor prognostic value, suggesting that an 
efficient DNA repair mechanism is required in the presence of high 
aldehyde metabolism (261). Finally, an increased expression of Lig 
I has been reported in breast and lung tumour tissues (262).
Very importantly, along with the levels of the proteins, it is also 
fundamental to evaluate their activity, as biomarkers. The possi-
bility to measure the DNA repair capacity (DRC) could provide a 
method to predict the outcome of a particular disease. For instance, 
5-fluorouracil (5-FU) is the main chemotherapeutic drug used against 
solid tumours. The BER pathway is involved in the DNA repair pro-
cess in response to 5-FU lesions, thus, removing 5-FU and uracil me-
tabolites from the DNA (263). A  prospective study demonstrated 
the association between DRC of BER in response to 5-FU and pa-
tient survival in a cohort affected by CRC. In the study, the overall 
survival was correlated with high activity of BER in non-malignant 
adjacent mucosa and low BER in tumour tissue in patients with 
TNM Stages II and III, together with good therapy response (264). 
Interestingly, APE1 enzymatic activity was also higher in gallbladder 
tumour patients than in chronic cholecystitis patients (225). Taking 
into account these results, Chaim et al. (265) developed a fluorescent-
based multiplex flow-cytometric host cell reactivation assay, based 
on the transfection of reporter plasmids in primary T lymphocytes, 
that allowed measurement of the activity of BER enzymes, such as 
different glycosylases (OGG1, MPG, MUTYH and UNG) and APE1. 
The possibility to measure the activity of OGG1 and MPG through a 
DNA glycosylase-mediated cleavage of molecular beacons was dem-
onstrated by Hu et al. (266).
BER polymorphisms and cancer
The identification of single-nucleotide polymorphisms (SNPs) in 
DNA repair genes has become increasingly important since they 
can determine a different DNA repair capacity and consequently 
generate higher frequency of mutations (267). Therefore, SNPs can 
be associated with a high susceptibility to cancer and with chemo-
therapy and radiotherapy resistance (268). Different SNPs involved 
in carcinogenesis have been identified in the main DNA repair path-
ways, such as BER, NER, MMR and double-strand breaks repair 
(DSBR) (267,269,270). For all these reasons, DNA repair pathway 
polymorphisms are of interest as predictive factors in the clinic. 
Here, we report the most frequent functional polymorphisms that 
have recently been published concerning the BER pathway enzymes 
(see Wallace et al. (14) for the complete list of polymorphisms).
Several evidences have been reported regarding the main BER 
DNA glycosylases, such as OGG1, NEIL3 and mutY DNA glycosylase 
(MUTYH). Several studies have been reported regarding the most 
studied OGG1 polymorphic variant: Ser326Cys (rs1052133). Up to 
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now, data regarding OGG1 Ser326Cys polymorphism and cancer 
has been conflicting, probably due to the susceptibly of the different 
populations and the different types of tumours that have been studied. 
Earlier evidence suggested that OGG1 Ser326Cys polymorphism did 
not increase the risk of developing lung cancer (271). Nevertheless, 
conflicting data of OGG1 Ser326Cys polymorphism was present for 
CRC (272,273) and breast cancer (274,275). However, a more re-
cent study has shown how OGG1 Ser326Cys heterozygous geno-
type (Ser/Cys) is associated with a decrease of bladder cancer risk 
in a cohort of a Belarusian population (276). In a follow-up study, 
the same research group demonstrated how this polymorphism 
could affect cancer-related genes and the methylation status in pa-
tients diagnosed with bladder cancer. Indeed, the frequency of the 
oncogenic phosphatidylinositol 3-kinase (PIK3CA) mutations was 
reduced in smokers of heterozygous genotype (Ser/Cys) and minor 
allele (Cys) carriers. On the contrary, the same polymorphism correl-
ated with an increased frequency of mutations in the RAS loci and 
affected the levels of runt-related transcription factor 3 (RUNX3) 
and ISL LIM homeobox 1 (ISL1) methylation (277). In addition, 
it has been shown that OGG1 Ser326Cys homozygous genotype 
(Cys/Cys) represents a risk factor for childhood leukaemia (278). An 
explanation is that the Cys/Cys genotype is associated with lower 
OGG1 activity, which translates to an increased AML relapse (279). 
Concerning polymorphisms involving other glycosylases, NEIL3 
Pro117Arg (rs7689099) has been suggested for its relevance in sus-
ceptibility, survival and therapy outcome in patients with CRC from 
the Czech Republic and Austrian cohorts (280). Finally, MUTYH 
polymorphism Gln324His (rs3219489) (Gln/His and His/His) was 
associated with increased CRC risk in a Polish population (281) and 
Gln324His (His/His) was linked to an higher lung cancer risk in a 
Japanese population (271).
Concerning the endonuclease APE1, the most frequent poly-
morphism is Asp148Glu (rs3136820), covering about 46% of the 
population (14). Again, conflicting data are present in the litera-
ture regarding bladder, breast, colorectal and lung cancer (14,270). 
Furthermore, a recent meta-analysis has not shown any associ-
ation between the Asp148Glu polymorphism and prostate cancer; 
however, in the same study, when a hospital-based population was 
considered, the presence of Asp148Glu dominant variants (Glu/
Glu and  Asp/Glu) was proposed as a risk factor to develop pros-
tate cancer (282). In addition, in a recent study, APE1 Asp148Glu 
was not considered as a risk factor for HCC in an Egyptian popula-
tion (283). These discrepancies probably are attributable to the fact 
that the Asp148Glu variant exhibits normal endonuclease activity 
(284). However, increasing incidence of AP sites has been observed 
in leukocytes derived from breast cancer patients compared to con-
trols, thus increasing the risk of cancer (285). Finally, a meta-analysis 
has suggested that the APE1 polymorphism rs1760944 T > G could 
have a protective role in cancer development among Asians (286).
Few data are available regarding the association between PARP1, 
Pol β, FEN1 polymorphisms and tumours. Liu et al. (270) have re-
ported the latest data regarding these BER enzyme polymorphisms 
and the risk of CRC.
Different studies concerning XRCC1 polymorphisms and the sus-
ceptibility to cancer have been reported. In a Caucasian population, 
the risk of gliomas was associated with both the homozygous vari-
ants of XRCC1 Gln399Gln and XRCC3 Met241Met (287). Another 
variant of XRCC1, Arg194Trp, was shown to be a risk factor for 
CRC in a Chinese and Kashmiri population with heterozygous (Arg/
Trp) and homozygous variants (Trp/Trp) (288,289). The same poly-
morphism was considered a susceptibility factor for HCV-related 
hepatocellular carcinoma progression in an Egyptian population; 
however, no association was found when Arg280His or Arg399Gln 
genotypes were taken into account (283). In a Chinese cohort, 
the polymorphism located at the promoter of XRCC1 (XRCC1 
rs3213245 C genotype) was associated with a decreased risk of cer-
vical cancer, due to a transcriptional overexpression of XRCC1, as a 
consequence of the enhanced binding of the Sp1-Knox-20 complex 
to the promoter region. Moreover, a decreased expression of XRCC1 
has been observed in carriers of the XRCC1 rs3213245 T genotype, 
increasing the risk of cancer (290). BER polymorphism can affect 
the methylation status of some tumour suppressor genes, as previ-
ously mentioned. For instance, focusing on XRCC1, in a study which 
considered a cohort of patients with bladder cancer, the XRCC1 
Arg399Gln (rs25487) heterozygous (Arg/Gln) genotype increased 
the frequency of p16 and TIMP3 methylation (277).
Extracellular secretion of BER proteins: novel 
insights in cancer biology
It has been widely reported how, in cancer cells, the activation of the 
BER pathway, in response to the chemotherapy treatment, promotes 
a resistant phenotype (291). Through the activation of repair mech-
anisms, in fact, stressed cancer cells can escape from cell death and 
maintain their ability to grow (292). This is the reason why BER en-
zymes are considered a good target for developing novel anti-cancer 
therapies. The chemoresistance phenomenon is not only connected 
with the activation of repair pathways in cancer cells, but also with 
the multifunctional role of the BER enzymes, particularly associ-
ated with the regulation of gene expression (133,293). Another 
interesting aspect supporting the chemoresistance occurrence is the 
capability of drug treatments to induce a modulation of the immune 
responses (294). Some secreted factors are also responsible for the 
modulation of immune responses, acting in the extracellular tu-
mour microenvironment, to affect the metabolism of the accepting 
cancer cells (293). This property suggests a new scenario regarding 
the dynamic molecular mechanisms that are activated by the se-
creted factors that influence the behavior of the surrounding cancer 
cells. Specifically, it would be interesting to study some BER or BER-
related proteins regarding their possible roles as damage associated 
molecular patterns (DAMP) proteins in tumour progression, such as 
the secreted protein high mobility group box 1 (HMGB1) (Figure 
1). HMGB1 is a nuclear DNA repair protein that acts as a chro-
matin remodeling factor and as a transcriptional regulator, but it is 
also an extracellular protein, that can act as a chemokine and cyto-
kine, having a role in cell signaling and inflammation (295,296). As a 
DNA repair protein, its accumulation is concomitant with oxidative 
DNA damage and, for this reason, it has been defined as an early 
DDR factor (297). It is also considered as a BER co-factor, because 
it is able to affect the activities of BER enzymes. HMGB1 stimulates 
APE1 endonuclease activity on AP sites, and promotes long-patch 
BER, through the stimulation of FEN1 flap cleavage activity (295). 
It is known that oxidative stress is responsible for HMGB1 trans-
location, release and activity (298). These secreted proteins therefore 
have a pro-inflammatory role (299). Indeed, HMGB1 secretion is in-
duced upon chemotherapeutic treatment, and due to its capability to 
stimulate the chemokine CXCL11, it contributes to the antitumour 
immune response (294,300). In contrast, current data elucidate how 
this secreted protein is also connected to cancer development, due to 
its role in the progression of esophageal squamous cell carcinoma 
(ESCC) (293). These data suggest the importance of activated para-
crine signaling in the tumour microenvironment for cancer evolution 
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and progression. Interestingly, other proteins whose role was ini-
tially thought to be restricted only to the nuclear compartment and 
with the maintenance of DNA structure and with the regulation of 
gene expression, have been recently demonstrated to play a role in 
paracrine signaling. Even if these proteins lack the leader sequence 
that promotes the canonical secretion through the endoplasmic re-
ticulum and Golgi apparatus (301), their secretion is clearly docu-
mented. As secreted factors, the function of these proteins seems to 
be related to cytokines activity. One example is YB-1, an additional 
APE1-interacting protein, whose role as an extracellular mitogen 
was described in mesangial and monocyte cells after inflammatory 
challenges (302) (Figure 1). There are also consistent data about the 
secretion of the APE1 enzyme, whose elevated intracellular protein 
levels in cancer are linked to poor prognosis (141). APE1 confers 
resistance to chemotherapy or radiotherapy treatments in different 
kind of tumours like gliomas, breast cancer, HCC, thyroid cancer 
and osteosarcoma (226,303–305). Recent findings concerning APE1 
cytoplasmic relocation and poor prognostic correlation in HCC cells 
led to new investigations about the multiple functions of this BER 
enzyme and to its emergent role in cancer progression relative to its 
own localisation (141,226). Studies regarding its possible secretion 
were reported since 2004, when it was predicted that APE1 was also 
a non-classically secreted protein (306). Its extracellular secretion 
was later revealed in the plasma of endotoxemic rats (307), and in 
the same year, the regulation of APE1 secretion occurring through 
PTMs and inducing its extracellular release was characterised. It 
seems, in fact, that the acetylation of residues K6/K7 in the APE1 
N-terminal region promotes its secretion (308). APE1 acetylation as 
a post-translational modification promoting its extracellular release, 
was also verified in TNBC, in which APE1 secretion and its action 
as an autocrine and paracrine factor seems to promote the apop-
tosis of cancer cells (309). Reports regarding APE1 functions as a 
secreted protein were also observed in monocytes, where an APE1 
extracellular role under inflammatory conditions and its capability 
to promote the production and secretion of IL-6 were proven (310). 
We recently demonstrated a role of extracellular APE1 in HCC 
(311), finding a positive correlation between serum and tissue APE1 
amounts in the HCC cohort analysed. These data prompted us to 
consider serum APE1 as a new diagnostic biomarker in HCC. We 
also showed that the exogenous APE1 protein was able to induce 
IL-6 and IL-8 expression in the JHH-6 HCC cell line, suggesting its 
role as a paracrine pro-inflammatory factor. Hence, these findings 
suggested that exogenous APE1 was able to modulate the inflamma-
tory status of the tumour microenvironment, showing its possible 
role in cellular senescence and in tumour invasiveness (310–312). We 
believe that further characterisation of the roles of secreted BER pro-
teins is required for an understanding of their role in tumour biology.
Cancer organoids as a novel approach to 
translate BER proteins in personalised 
medicine
Human cell lines and in vivo animal models have been largely 
used to characterise the biochemical functions and the biological 
relevance of BER proteins, and are a well-known model in cancer 
translational research. However, a better knowledge of the adult 
stem cells in combination with three-dimensional (3D) cultures 
has allowed the establishment of organoids as an advanced model 
Figure 3. Protein–protein interaction network of proteins involved in DNA repair/stability and in RNA processing. Data, obtained from the InWeb_InBioMap 
platform (no network expansion, confidence score cut-off = 0.156 [recommended value]; (322)), shows the direct (solid lines) and indirect (dashed lines) 
interactions existing between BER (yellow nodes), nucleotide excision repair/DNA mismatch repair/non-homologous end joining (NER, MMR, NHEJ, red nodes), 
homologous recombination (HR, cyan nodes), telomeres (purple nodes) and RNA processing/binding (green nodes) proteins, as well as a few others (blue 
nodes) with heterogeneous molecular functions. Figure available in colour online.
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system (313,314). Organoids consist of a novel 3D technology, 
which allows the establishment of long-term stem cell-based cul-
tures. Organoids represent a valuable tool to study the biology 
of stem cells and to evaluate their contribution to tissue homeo-
stasis. Organoids have numerous valuable applications and may 
be used to improve our knowledge about several disease path-
ways (315,316), especially in cancer biology. Due to the intriguing 
mechanisms characterising tumour aetiology, different studies 
have focused on personalised precision treatments for cancer. By 
using patient-derived tumour organoids (PDOs), studies have tried 
to understand and reproduce the disease complexity and hetero-
geneity, for developing patient-specific therapies (317), because 
organoids reflect the key-features of the original patient’s tissue 
(316). Different types of analyses involving normal and tumour 
PDOs have been performed, such as genome, transcriptome (318) 
and proteome analyses (317), but DNA repair mechanisms have 
not been extensively studied. Based on previous studies, normal 
organoids could be engineered to study DNA repair enzymes defi-
ciencies and evaluate mutational signatures in cancer. To date, few 
studies regarding BER enzymes and PDOs have been published. 
In a recent study, human normal intestinal organoids were engin-
eered with the CRISPR-Cas9 genome editing system to delete key 
DNA repair genes, such as the MMR gene MLH1 and the BER 
gene NTHL1 (319). This approach proved that MLH1 knock-
out organoids reflected mismatch repair-deficiency found in CRC; 
moreover, the lack of NTHL1 was a predisposition to the devel-
opment of a range of cancers, such as colorectal and breast cancer 
(319). Furthermore, the opportunity to perform drug-screening as-
says on PDOs is very appealing, considering that chemoresistance 
can occur in patients (320). Indeed, we recently tested the APE1 
endonuclease inhibitor (Compound #3) on CRC PDOs, carrying a 
wild-type, and a stop-gain or missense mutant TP53, highlighting 
that the effectiveness of the inhibitor was dependent on the presence 
of wild-type or gained-of-function mutant p53 and independent of 
the null-mutant p53 (321). Therefore, we strongly believe that the 
use of these 3D-cell models should be carefully considered in trans-
lating BER biochemistry into personalised medicine.
Conclusions
Forty years after the first characterisation of the BER glycosylases, 
integration of this pathway (Figure 3, yellow nodes) within the 
DDR (Figure 3, red and cyan nodes) has been somewhat elucidated. 
The recent discovery of a functional role of this highly conserved 
pathway in genomic stability, gene expression regulation and RNA 
processing/decay (Figure 3, purple, blue and green nodes) lays the 
foundations for the starting point of a new challenging field of re-
search. These achievements will significantly contribute to our 
understanding of the complexity of BER and the DDR, in general. 
Moreover, these findings will help add further elements to the com-
prehension of the role of BER in human physiology and pathology, 
possibly opening new unpredicted therapeutic perspectives. Many 
issues still remain to be addressed and are prompting researchers 
to continue their efforts to understand the crosstalk between DNA 
damage and gene expression regulation. This can be considered as a 
fundamental process responsible for the adaptive cellular mechan-
isms to genotoxic damage, and is a concern regarding several pos-
sible mechanisms of cancer chemoresistance.
In the last 40 years, we have learned much regarding BER bio-
chemistry and biology. However, a number of questions still remain 
to be elucidated.
• Should we reinterpret the overall biological function of DDR and 
its role in cancer based on the data about the relevance of the 
non-canonical functions of DDR and BER proteins?
• Several BER and other DDR enzymes are catalytically active on 
different modified RNA substrates. Should we ascribe to them an 
important role in RNA decay or in the editing mechanisms?
• Might the unique ability of BER DNA glycosylases to recognise 
even subtle chemical modifications of nucleobases serve to distin-
guish between normal and aberrant RNA molecules?
• Is there a concerted action between DNA glycosylases, APE1 and 
the downstream enzymes involved in decay/repair of damaged 
RNA molecules?
• Can the effects of BER enzymes, both on mRNA and ncRNA, 
alter the protein translational machinery, thus, contributing to 
chemoresistance through post-transcriptional regulation of gene 
expression?
• Is the role of some DNA repair proteins in secreted exosomal 
particles due to their canonical or non-canonical functions?
In 2009, thanks to the use of unbiased proteomics and genomics 
strategies, we were able to propose the novel concept of non-
canonical functions of APE1 in RNA metabolism. We strongly be-
lieve that an integrated view of the canonical roles of BER proteins 
in DNA repair and in RNA functions will lead to new important and 
unexpected discoveries in the future.
Funding
This work was supported by grants from the Associazione Italiana per la 
Ricerca sul Cancro (IG14038) and the European Union, European Regional 
Development Fund and Interreg V-A Italia-Austria 2014-2020 ITAT1096-P 
(Program PRECANMED ITAT1009 CUP G22F16000890006) to G.T.
Acknowledgements
The authors thank all the members of the GT lab for constructive feedback 
during the development of this work.
Conflict of interest statement: None declared.
References
 1. Hein,  N., Hannan,  K.  M., George,  A.  J., Sanij,  E. and Hannan,  R.  D. 
(2013) The nucleolus: an emerging target for cancer therapy. Trends Mol. 
Med., 19, 643–654.
 2. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next 
generation. Cell, 144, 646–674.
 3. Wickramasinghe, V. O. and Venkitaraman, A. R. (2016) RNA processing 
and genome stability: cause and consequence. Mol. Cell, 61, 496–505.
 4. Michelini, F., Jalihal, A. P., Francia, S., et al. (2018) From “cellular” RNA 
to “smart” RNA: multiple roles of RNA in genome stability and beyond. 
Chem. Rev., 118, 4365–4403.
 5. Antoniali, G., Lirussi, L., Poletto, M. and Tell, G. (2014) Emerging roles of 
the nucleolus in regulating the DNA damage response: the noncanonical 
DNA repair enzyme APE1/Ref-1 as a paradigmatical example. Antioxid. 
Redox Signal., 20, 621–639.
 6. Antoniali, G., Serra, F., Lirussi, L., et al. (2017) Mammalian APE1 con-
trols miRNA processing and its interactome is linked to cancer RNA me-
tabolism. Nat. Commun., 8, 797.
 7. Malfatti, M. C., Balachander, S., Antoniali, G., et al. (2017) Abasic and 
oxidized ribonucleotides embedded in DNA are processed by human 
APE1 and not by RNase H2. Nucleic Acids Res., 45, 11193–11212.
 8. Dianov,  G.  L., Souza-Pinto,  N., Nyaga,  S.  G., Thybo,  T., Stevnsner,  T. 
and Bohr, V. A. (2001) Base excision repair in nuclear and mitochondrial 
DNA. Prog. Nucleic Acid Res. Mol. Biol., 68, 285–297.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 9. Krokan, H. E. and Bjørås, M. (2013) Base excision repair. Cold Spring 
Harb. Perspect. Biol., 5, a012583.
 10. Markkanen, E. (2017) Not breathing is not an option: how to deal with 
oxidative DNA damage. DNA Repair (Amst)., 59, 82–105.
 11. Sidorenko, V. S., Nevinsky, G. A. and Zharkov, D. O. (2007) Mechanism 
of interaction between human 8-oxoguanine-DNA glycosylase and AP 
endonuclease. DNA Repair (Amst)., 6, 317–328.
 12. Sidorenko, V. S. and Zharkov, D. O. (2008) Role of base excision repair 
DNA glycosylases in hereditary and infectious human diseases. Mol. Biol., 
42,794–805.
 13. Takao,  M., Zhang,  Q.  M., Yonei,  S. and Yasui,  A. (1999) Differential 
subcellular localization of human MutY homolog (hMYH) and the func-
tional activity of adenine:8-oxoguanine DNA glycosylase. Nucleic Acids 
Res., 27, 3638–3644.
 14. Wallace, S. S., Murphy, D. L. and Sweasy, J. B. (2012) Base excision repair 
and cancer. Cancer Lett., 327, 73–89.
 15. Svilar, D., Goellner, E. M., Almeida, K. H. and Sobol, R. W. (2011) Base 
excision repair and lesion-dependent subpathways for repair of oxidative 
DNA damage. Antioxid. Redox Signal., 14, 2491–2507.
 16. Hill,  J. W., Hazra, T. K., Izumi, T. and Mitra,  S. (2001) Stimulation of 
human 8-oxoguanine-DNA glycosylase by AP-endonuclease: potential co-
ordination of the initial steps in base excision repair. Nucleic Acids Res., 
29, 430–438.
 17. Prakash, A., Doublié, S. and Wallace, S. S. (2012) The Fpg/Nei family of 
DNA glycosylases: substrates, structures, and search for damage. Prog. 
Mol. Biol. Transl. Sci., 110, 71–91.
 18. Bailly, V. and Verly, W. G. (1988) Possible roles of beta-elimination and 
delta-elimination reactions in the repair of DNA containing AP (apurinic/
apyrimidinic) sites in mammalian cells. Biochem. J., 253, 553–559.
 19. Iyama,  T. and Wilson,  D.  M., III. (2013) DNA repair mechanisms in 
dividing and non-dividing cells. DNA Repair (Amst)., 12, 620–636.
 20. Bauer, N. C., Corbett, A. H. and Doetsch, P. W. (2015) The current state of 
eukaryotic DNA base damage and repair. Nucleic Acids Res., 43, 10083–
10101.
 21. Dianov, G. L. and Hübscher, U. (2013) Mammalian base excision repair: 
the forgotten archangel. Nucleic Acids Res., 41, 3483–3490.
 22. Lindahl, T. (1993) Instability and decay of the primary structure of DNA. 
Nature, 362, 709–715.
 23. Loeb, L. A. and Preston, B. D. (1986) Mutagenesis by apurinic/apyrimidinic 
sites. Annu. Rev. Genet., 20, 201–230.
 24. Demple, B., Herman, T. and Chen, D. S. (1991) Cloning and expression of 
APE, the cDNA encoding the major human apurinic endonuclease: defin-
ition of a family of DNA repair enzymes. Proc. Natl. Acad. Sci. U. S. A., 
88, 11450–11454.
 25. Hadi, M. Z., Ginalski, K., Nguyen, L. H. and Wilson, D. M., III. (2002) 
Determinants in nuclease specificity of Ape1 and Ape2, human homo-
logues of Escherichia coli exonuclease III. J. Mol. Biol., 316, 853–866.
 26. Meira,  L.  B., Devaraj,  S., Kisby,  G.  E., Burns,  D.  K., Daniel,  R.  L., 
Hammer, R. E., Grundy, S., Jialal, I. and Friedberg, E. C. (2001) Hetero-
zygosity for the mouse Apex gene results in phenotypes associated with 
oxidative stress. Cancer Res., 61, 5552–5557.
 27. Gorman, M. A., Morera, S., Rothwell, D. G., de La Fortelle, E., Mol, C. D., 
Tainer, J. A., Hickson, I. D. and Freemont, P. S. (1997) The crystal struc-
ture of the human DNA repair endonuclease HAP1 suggests the recog-
nition of extra-helical deoxyribose at DNA abasic sites. EMBO J., 16, 
6548–6558.
 28. Tell, G., Quadrifoglio, F., Tiribelli, C. and Kelley, M. R. (2009) The many 
functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox 
Signal., 11, 601–620.
 29. Whitaker, A. M. and Freudenthal, B. D. (2018) APE1: a skilled nucleic acid 
surgeon. DNA Repair (Amst)., 71, 93–100.
 30. Erzberger, J. P. and Wilson, D. M., III. (1999) The role of Mg2+ and specific 
amino acid residues in the catalytic reaction of the major human abasic 
endonuclease: new insights from EDTA-resistant incision of acyclic abasic 
site analogs and site-directed mutagenesis. J. Mol. Biol., 290, 447–457.
 31. Freudenthal,  B.  D., Beard,  W.  A., Cuneo,  M.  J., Dyrkheeva,  N.  S. and 
Wilson,  S.  H. (2015) Capturing snapshots of APE1 processing DNA 
damage. Nat. Struct. Mol. Biol., 22, 924–931.
 32. Beernink, P. T., Segelke, B. W., Hadi, M. Z., Erzberger, J. P., Wilson, D. M., 
III and Rupp, B. (2001) Two divalent metal ions in the active site of a new 
crystal form of human apurinic/apyrimidinic endonuclease, Ape1: implica-
tions for the catalytic mechanism. J. Mol. Biol., 307, 1023–1034.
 33. Mol, C. D., Izumi, T., Mitra, S. and Tainer, J. A. (2000) DNA-bound struc-
tures and mutants reveal abasic DNA binding by APE1 and DNA repair 
coordination [corrected]. Nature, 403, 451–456.
 34. Marenstein, D. R., Wilson, D. M., III and Teebor, G. W. (2004) Human 
AP endonuclease (APE1) demonstrates endonucleolytic activity against AP 
sites in single-stranded DNA. DNA Repair (Amst)., 3, 527–533.
 35. Chou, K. M. and Cheng, Y. C. (2003) The exonuclease activity of human 
apurinic/apyrimidinic endonuclease (APE1). Biochemical properties and 
inhibition by the natural dinucleotide Gp4G. J. Biol. Chem., 278, 18289–
18296.
 36. Wilson, D. M. 3rd. (2003) Properties of and substrate determinants for the 
exonuclease activity of human apurinic endonuclease Ape1. J. Mol. Biol., 
330, 1027–1037.
 37. Izumi, T., Brown, D. B., Naidu, C. V., Bhakat, K. K., Macinnes, M. A., 
Saito, H., Chen, D. J. and Mitra, S. (2005) Two essential but distinct func-
tions of the mammalian abasic endonuclease. Proc. Natl. Acad. Sci. U. S. 
A., 102, 5739–5743.
 38. Fantini, D., Vascotto, C., Marasco, D., et al. (2010) Critical lysine residues 
within the overlooked N-terminal domain of human APE1 regulate its 
biological functions. Nucleic Acids Res., 38, 8239–8256.
 39. Vascotto, C., Cesaratto, L., Zeef, L. A., et al. (2009) Genome-wide ana-
lysis and proteomic studies reveal APE1/Ref-1 multifunctional role in 
mammalian cells. Proteomics, 9, 1058–1074.
 40. Vascotto, C., Lirussi, L., Poletto, M., et al. (2014) Functional regulation 
of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on 
tumor biology. Oncogene, 33, 2876–2887.
 41. Tell,  G. and Demple,  B. (2015) Base excision DNA repair and cancer. 
Oncotarget, 6, 584–585.
 42. Busso, C. S., Iwakuma, T. and Izumi, T. (2009) Ubiquitination of mam-
malian AP endonuclease (APE1) regulated by the p53-MDM2 signaling 
pathway. Oncogene, 28, 1616–1625.
 43. Huang,  E., Qu,  D., Zhang,  Y., Venderova,  K., Haque,  M.  E., 
Rousseaux, M. W., Slack, R. S., Woulfe, J. M. and Park, D. S. (2010) The 
role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphoryl-
ation in neuronal death. Nat. Cell Biol., 12, 563–571.
 44. Busso, C. S., Lake, M. W. and Izumi, T. (2010) Posttranslational modifi-
cation of mammalian AP endonuclease (APE1). Cell. Mol. Life Sci., 67, 
3609–3620.
 45. Yoshida,  A., Urasaki,  Y., Waltham,  M., et  al. (2003) Human apurinic/
apyrimidinic endonuclease (Ape1) and its N-terminal truncated form 
(AN34) are involved in DNA fragmentation during apoptosis. J. Biol. 
Chem., 278, 37768–37776.
 46. Roychoudhury,  S., Nath,  S., Song,  H., et  al. (2017) Human apurinic/
apyrimidinic endonuclease (APE1) is acetylated at DNA damage sites in 
chromatin, and acetylation modulates its DNA repair activity. Mol. Cell. 
Biol., 37, e00401–e00416.
 47. Lirussi, L., Antoniali, G., Vascotto, C., et al. (2012) Nucleolar accumula-
tion of APE1 depends on charged lysine residues that undergo acetylation 
upon genotoxic stress and modulate its BER activity in cells. Mol. Biol. 
Cell, 23, 4079–4096.
 48. Burra,  S., Marasco,  D., Malfatti,  M.  C., Antoniali,  G., Virgilio,  A., 
Esposito,  V., Demple,  B., Galeone,  A. and Tell,  G. (2019) Human 
AP-endonuclease (Ape1) activity on telomeric G4 structures is modulated 
by acetylatable lysine residues in the N-terminal sequence. DNA Repair 
(Amst)., 73, 129–143.
 49. Sobol, R. W., Horton, J. K., Kühn, R., Gu, H., Singhal, R. K., Prasad, R., 
Rajewsky, K. and Wilson, S. H. (1996) Requirement of mammalian DNA 
polymerase-beta in base-excision repair. Nature, 379, 183–186.
 50. Sung,  J.  S., DeMott, M. S. and Demple, B. (2005) Long-patch base ex-
cision DNA repair of 2-deoxyribonolactone prevents the formation of 
DNA-protein cross-links with DNA polymerase beta. J. Biol. Chem., 280, 
39095–39103.
 51. Wilson, S. H. and Kunkel, T. A. (2000) Passing the baton in base excision 
repair. Nat. Struct. Biol., 7, 176–178.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 52. Almeida, K. H. and Sobol, R. W. (2007) A unified view of base excision re-
pair: lesion-dependent protein complexes regulated by post-translational 
modification. DNA Repair (Amst)., 6, 695–711.
 53. Allinson,  S.  L., Sleeth,  K.  M., Matthewman,  G.  E. and Dianov,  G.  L. 
(2004) Orchestration of base excision repair by controlling the rates of 
enzymatic activities. DNA Repair (Amst)., 3, 23–31.
 54. Déry, U. and Masson, J. Y. (2007) Twists and turns in the function of DNA 
damage signaling and repair proteins by post-translational modifications. 
DNA Repair (Amst)., 6, 561–577.
 55. Fan,  J. and Wilson,  D.  M., III. (2005) Protein-protein interactions and 
posttranslational modifications in mammalian base excision repair. Free 
Radic. Biol. Med., 38, 1121–1138.
 56. Vascotto, C., Fantini, D., Romanello, M., et al. (2009) APE1/Ref-1 inter-
acts with NPM1 within nucleoli and plays a role in the rRNA quality 
control process. Mol. Cell. Biol., 29, 1834–1854.
 57. Khodyreva,  S.  N., Prasad,  R., Ilina,  E.  S., Sukhanova,  M.  V., 
Kutuzov,  M.  M., Liu,  Y., Hou,  E.  W., Wilson,  S.  H. and Lavrik,  O.  I. 
(2010) Apurinic/apyrimidinic (AP) site recognition by the 5′-dRP/AP lyase 
in poly(ADP-ribose) polymerase-1 (PARP-1). Proc. Natl. Acad. Sci. U. S. 
A., 107, 22090–22095.
 58. Prasad, R., Dyrkheeva, N., Williams, J. and Wilson, S. H. (2015) Mam-
malian base excision repair: functional partnership between PARP-1 and 
APE1 in AP-site repair. PLoS One, 10, e0124269.
 59. Alseth, I., Eide, L., Pirovano, M., Rognes, T., Seeberg, E. and Bjørås, M. 
(1999) The Saccharomyces cerevisiae homologues of endonuclease III 
from Escherichia coli, Ntg1 and Ntg2, are both required for efficient re-
pair of spontaneous and induced oxidative DNA damage in yeast. Mol. 
Cell. Biol., 19, 3779–3787.
 60. Blaisdell, J. O. and Wallace, S. S. (2001) Abortive base-excision repair of 
radiation-induced clustered DNA lesions in Escherichia coli. Proc. Natl. 
Acad. Sci. U. S. A., 98, 7426–7430.
 61. Friedberg, E. C., Meira, L. B. and Cheo, D. L. (1997) Database of mouse 
strains carrying targeted mutations in genes affecting cellular responses to 
DNA damage. Mutat. Res., 383, 183–188.
 62. Gros, L., Ishchenko, A. A., Ide, H., Elder, R. H. and Saparbaev, M. K. 
(2004) The major human AP endonuclease (APE1) is involved in the nu-
cleotide incision repair pathway. Nucleic Acids Res., 32, 73–81.
 63. Timofeyeva, N. A., Koval, V. V., Ishchenko, A. A., Saparbaev, M. K. and 
Fedorova, O. S. (2011) Lys98 substitution in human AP endonuclease 1 
affects the kinetic mechanism of enzyme action in base excision and nu-
cleotide incision repair pathways. PLoS One, 6, e24063.
 64. Ishchenko, A. A., Deprez, E., Maksimenko, A., Brochon,  J. C., Tauc, P. 
and Saparbaev, M. K. (2006) Uncoupling of the base excision and nucleo-
tide incision repair pathways reveals their respective biological roles. Proc. 
Natl. Acad. Sci. U. S. A., 103, 2564–2569.
 65. Gelin, A., Redrejo-Rodríguez, M., Laval, J., Fedorova, O. S., Saparbaev, M. 
and Ishchenko, A. A. (2010) Genetic and biochemical characterization of 
human AP endonuclease 1 mutants deficient in nucleotide incision repair 
activity. PLoS One, 5, e12241.
 66. Daviet, S., Couvé-Privat, S., Gros, L., Shinozuka, K., Ide, H., Saparbaev, M. 
and Ishchenko, A. A. (2007) Major oxidative products of cytosine are sub-
strates for the nucleotide incision repair pathway. DNA Repair (Amst)., 6, 
8–18.
 67. Redrejo-Rodríguez,  M., Vigouroux,  A., Mursalimov,  A., et  al. (2016) 
Structural comparison of AP endonucleases from the exonuclease III 
family reveals new amino acid residues in human AP endonuclease 1 that 
are involved in incision of damaged DNA. Biochimie, 128–129, 20–33.
 68. Kim, K., Biade, S. and Matsumoto, Y. (1998) Involvement of flap endo-
nuclease 1 in base excision DNA repair. J. Biol. Chem., 273, 8842–8848.
 69. Klungland, A. and Lindahl, T. (1997) Second pathway for completion of 
human DNA base excision-repair: reconstitution with purified proteins 
and requirement for DNase IV (FEN1). EMBO J., 16, 3341–3348.
 70. Ischenko, A. A. and Saparbaev, M. K. (2002) Alternative nucleotide inci-
sion repair pathway for oxidative DNA damage. Nature, 415, 183–187.
 71. Ide, H., Tedzuka, K., Shimzu, H., Kimura, Y., Purmal, A. A., Wallace, S. S. 
and Kow, Y. W. (1994) Alpha-deoxyadenosine, a major anoxic radiolysis 
product of adenine in DNA, is a substrate for Escherichia coli endo-
nuclease IV. Biochemistry, 33, 7842–7847.
 72. Jorgensen, T. J., Furlong, E. A. and Henner, W. D. (1988) Gamma endo-
nuclease of Micrococcus luteus: action on irradiated DNA. Radiat. Res., 
114, 556–566.
 73. Lesiak, K. B. and Wheeler, K. T. (1990) Formation of alpha-deoxyadenosine 
in polydeoxynucleotides exposed to ionizing radiation under anoxic con-
ditions. Radiat. Res., 121, 328–337.
 74. Dizdaroglu, M., Laval,  J. and Boiteux, S. (1993) Substrate specificity of 
the Escherichia coli endonuclease III: excision of thymine- and cytosine-
derived lesions in DNA produced by radiation-generated free radicals. 
Biochemistry, 32, 12105–12111.
 75. Ishchenko, A. A., Ide, H., Ramotar, D., Nevinsky, G. and Saparbaev, M. 
(2004) Alpha-anomeric deoxynucleotides, anoxic products of ionizing 
radiation, are substrates for the endonuclease IV-type AP endonucleases. 
Biochemistry, 43, 15210–15216.
 76. Abad, J. P. and Villasante, A. (1999) The 3′ non-coding region of the Dros-
ophila melanogaster HeT-A telomeric retrotransposon contains sequences 
with propensity to form G-quadruplex DNA. FEBS Lett., 453, 59–62.
 77. Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., 
Jones, M. D., Meyne, J., Ratliff, R. L. and Wu, J. R. (1988) A highly con-
served repetitive DNA sequence, (TTAGGG)n, present at the telomeres of 
human chromosomes. Proc. Natl. Acad. Sci. U. S. A., 85, 6622–6626.
 78. de Lange, T. (2005) Shelterin: the protein complex that shapes and safe-
guards human telomeres. Genes Dev., 19, 2100–2110.
 79. Oganesian, L. and Karlseder, J. (2009) Telomeric armor: the layers of end 
protection. J. Cell Sci., 122, 4013–4025.
 80. Huppert, J. L. (2008) Four-stranded nucleic acids: structure, function and 
targeting of G-quadruplexes. Chem. Soc. Rev., 37, 1375–1384.
 81. Fleming,  A.  M. and Burrows,  C.  J. (2013) G-quadruplex folds of the 
human telomere sequence alter the site reactivity and reaction pathway 
of guanine oxidation compared to duplex DNA. Chem. Res. Toxicol., 26, 
593–607.
 82. Zhou, J., Liu, M., Fleming, A. M., Burrows, C. J. and Wallace, S. S. (2013) 
Neil3 and NEIL1 DNA glycosylases remove oxidative damages from 
quadruplex DNA and exhibit preferences for lesions in the telomeric se-
quence context. J. Biol. Chem., 288, 27263–27272.
 83. Zhou, J., Fleming, A. M., Averill, A. M., Burrows, C. J. and Wallace, S. S. 
(2015) The NEIL glycosylases remove oxidized guanine lesions from telo-
meric and promoter quadruplex DNA structures. Nucleic Acids Res., 43, 
4039–4054.
 84. Zhou, J., Chan, J., Lambelé, M., Yusufzai, T., Stumpff, J., Opresko, P. L., 
Thali, M. and Wallace, S. S. (2017) NEIL3 repairs telomere damage during 
S phase to secure chromosome segregation at mitosis. Cell Rep., 20, 2044–
2056.
 85. Li, M., Yang, X., Lu, X., et al. (2018) APE1 deficiency promotes cellular 
senescence and premature aging features. Nucleic Acids Res., 46, 5664–
5677.
 86. Madlener, S., Ströbel, T., Vose, S., Saydam, O., Price, B. D., Demple, B. and 
Saydam,  N. (2013) Essential role for mammalian apurinic/apyrimidinic 
(AP) endonuclease Ape1/Ref-1 in telomere maintenance. Proc. Natl. Acad. 
Sci. U. S. A., 110, 17844–17849.
 87. Stavnezer,  J., Guikema,  J.  E. and Schrader,  C.  E. (2008) Mechanism 
and regulation of class switch recombination. Annu. Rev. Immunol., 26, 
261–292.
 88. Masani,  S., Han,  L. and Yu,  K. (2013) Apurinic/apyrimidinic endo-
nuclease 1 is the essential nuclease during immunoglobulin class switch 
recombination. Mol. Cell. Biol., 33, 1468–1473.
 89. Schrader, C. E., Guikema,  J. E., Wu, X. and Stavnezer,  J. (2009) The 
roles of APE1, APE2, DNA polymerase beta and mismatch repair in cre-
ating S region DNA breaks during antibody class switch. Philos. Trans. 
R. Soc. Lond. B. Biol. Sci., 364, 645–652.
 90. Guikema,  J.  E.  J., Linehan,  E.  K., Tsuchimoto,  D., Nakabeppu,  Y., 
Strauss, P. R., Stavnezer, J. and Schrader, C. E. (2008) APE1- and APE2-
dependent DNA breaks in immunoglobulin class switch recombination. 
J. Exp. Med., 204,3295–3295.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 91. Akbari,  M., Otterlei,  M., Peña-Diaz,  J., et  al. (2004) Repair of U/G 
and U/A in DNA by UNG2-associated repair complexes takes place 
predominantly by short-patch repair both in proliferating and growth-
arrested cells. Nucleic Acids Res., 32, 5486–5498.
 92. Vuong, B. Q., Herrick-Reynolds, K., Vaidyanathan, B., et al. (2013) A 
DNA break- and phosphorylation-dependent positive feedback loop 
promotes immunoglobulin class-switch recombination. Nat. Immunol., 
14, 1183–1189.
 93. Vuong,  B.  Q. and Chaudhuri,  J. (2012) Combinatorial mechanisms 
regulating AID-dependent DNA deamination: interacting proteins and 
post-translational modifications. Semin. Immunol., 24, 264–272.
 94. Xu, J., Husain, A., Hu, W., Honjo, T. and Kobayashi, M. (2014) APE1 
is dispensable for S-region cleavage but required for its repair in class 
switch recombination. Proc. Natl. Acad. Sci. U.  S. A., 111, 17242–
17247.
 95. Islam, H., Kobayashi, M. and Honjo, T. (2019) Apurinic/apyrimidinic 
endonuclease 1 (APE1) is dispensable for activation-induced cytidine 
deaminase (AID)-dependent somatic hypermutation in the immuno-
globulin gene. Int. Immunol., 31, 543–554.
 96. Gostissa, M., Alt, F. W. and Chiarle, R. (2011) Mechanisms that pro-
mote and suppress chromosomal translocations in lymphocytes. Annu. 
Rev. Immunol., 29, 319–350.
 97. Tell, G., Fantini, D. and Quadrifoglio, F. (2010) Understanding different 
functions of mammalian AP endonuclease (APE1) as a promising tool 
for cancer treatment. Cell. Mol. Life Sci., 67, 3589–3608.
 98. Antoniali, G., Lirussi, L., D’Ambrosio, C., et al. (2014) SIRT1 gene ex-
pression upon genotoxic damage is regulated by APE1 through nCaRE-
promoter elements. Mol. Biol. Cell, 25, 532–547.
 99. Frossi,  B., Antoniali,  G., Yu,  K., Akhtar,  N., Kaplan,  M.  H., 
Kelley, M. R., Tell, G. and Pucillo, C. E. M. (2019) Endonuclease and 
redox activities of human apurinic/apyrimidinic endonuclease 1 have 
distinctive and essential functions in IgA class switch recombination. J. 
Biol. Chem., 294, 5198–5207.
 100. Fong, Y. W., Cattoglio, C. and Tjian, R. (2013) The intertwined roles of 
transcription and repair proteins. Mol. Cell, 52, 291–302.
 101. Fleming, A. M., Ding, Y. and Burrows, C.  J. (2017) Oxidative DNA 
damage is epigenetic by regulating gene transcription via base excision 
repair. Proc. Natl. Acad. Sci. U. S. A., 114, 2604–2609.
 102. Fleming, A. M. and Burrows, C. J. (2017) 8-Oxo-7,8-dihydroguanine, 
friend and foe: epigenetic-like regulator versus initiator of mutagenesis. 
DNA Repair (Amst)., 56, 75–83.
 103. Dizdaroglu,  M. (2012) Oxidatively induced DNA damage: mechan-
isms, repair and disease. Cancer Lett., 327, 26–47.
 104. Kumar,  S., Chinnusamy, V. and Mohapatra, T. (2018) Epigenetics of 
modified DNA bases: 5-methylcytosine and beyond. Front. Genet., 9, 
640.
 105. Jena,  N.  R. and Mishra,  P.  C. (2005) Mechanisms of formation of 
8-oxoguanine due to reactions of one and two OH* radicals and the 
H2O2 molecule with guanine: a quantum computational study. J. Phys. 
Chem. B, 109, 14205–14218.
 106. Zarakowska,  E., Gackowski,  D., Foksinski,  M. and Olinski,  R. 
(2014) Are 8-oxoguanine (8-oxoGua) and 5-hydroxymethyluracil 
(5-hmUra) oxidatively damaged DNA bases or transcription (epi-
genetic) marks? Mutat. Res. Genet. Toxicol. Environ. Mutagen., 
764–765, 58–63.
 107. Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H. and Sakumi, K. (2007) 
Oxidative damage in nucleic acids and Parkinson’s disease. J. Neurosci. 
Res., 85, 919–934.
 108. Moreira, P. I., Nunomura, A., Nakamura, M., Takeda, A., Shenk, J. C., 
Aliev, G., Smith, M. A. and Perry, G. (2008) Nucleic acid oxidation in 
Alzheimer disease. Free Radic. Biol. Med., 44, 1493–1505.
 109. Sliwinska,  A., Kwiatkowski,  D., Czarny,  P., et  al. (2016) The levels 
of 7,8-dihydrodeoxyguanosine (8-oxoG) and 8-oxoguanine DNA 
glycosylase 1 (OGG1)—a potential diagnostic biomarkers of 
Alzheimer’s disease. J. Neurol. Sci., 368, 155–159.
 110. Pan, L., Zhu, B., Hao, W., et al. (2016) Oxidized guanine base lesions 
function in 8-oxoguanine DNA glycosylase-1-mediated epigenetic regu-
lation of nuclear factor κB-driven gene expression. J. Biol. Chem., 291, 
25553–25566.
 111. Ba, X. and Boldogh, I. (2018) 8-Oxoguanine DNA glycosylase 1: be-
yond repair of the oxidatively modified base lesions. Redox Biol., 14, 
669–678.
 112. Tornaletti, S. (2005) Transcription arrest at DNA damage sites. Mutat. 
Res., 577, 131–145.
 113. Allgayer,  J., Kitsera,  N., Bartelt,  S., Epe,  B. and Khobta,  A. (2016) 
Widespread transcriptional gene inactivation initiated by a repair inter-
mediate of 8-oxoguanine. Nucleic Acids Res., 44, 7267–7280.
 114. Ramon,  O., Sauvaigo,  S., Gasparutto,  D., Faure,  P., Favier,  A. and 
Cadet,  J. (1999) Effects of 8-oxo-7,8-dihydro-2′-deoxyguanosine on 
the binding of the transcription factor Sp1 to its cognate target DNA 
sequence (GC box). Free Radic. Res., 31, 217–229.
 115. Hailer-Morrison, M. K., Kotler, J. M., Martin, B. D. and Sugden, K. D. 
(2003) Oxidized guanine lesions as modulators of gene transcription. 
Altered p50 binding affinity and repair shielding by 7,8-dihydro-8-oxo-
2′-deoxyguanosine lesions in the NF-kappaB promoter element. Bio-
chemistry, 42, 9761–9770.
 116. Moore,  S.  P., Toomire,  K.  J. and Strauss,  P.  R. (2013) DNA modifi-
cations repaired by base excision repair are epigenetic. DNA Repair 
(Amst)., 12, 1152–1158.
 117. Perillo, B., Ombra, M. N., Bertoni, A., et al. (2008) DNA oxidation as 
triggered by H3K9me2 demethylation drives estrogen-induced gene ex-
pression. Science, 319, 202–206.
 118. Pastukh, V., Roberts,  J. T., Clark, D. W., Bardwell, G. C., Patel, M., 
Al-Mehdi, A. B., Borchert, G. M. and Gillespie, M. N. (2015) An oxi-
dative DNA “damage” and repair mechanism localized in the VEGF 
promoter is important for hypoxia-induced VEGF mRNA expression. 
Am. J. Physiol. Lung Cell. Mol. Physiol., 309, L1367–L1375.
 119. Fleming, A. M., Zhu, J., Ding, Y. and Burrows, C. J. (2017) 8-Oxo-7,8-
dihydroguanine in the context of a gene promoter G-quadruplex is an 
on-off switch for transcription. ACS Chem. Biol., 12, 2417–2426.
 120. Pan, L., Hao, W., Zheng, X., Zeng, X., Ahmed Abbasi, A., Boldogh, I. 
and Ba, X. (2017) OGG1–DNA interactions facilitate NF-κB binding to 
DNA targets. Sci. Rep., 7, 43297.
 121. Mabley, J. G., Pacher, P., Deb, A., Wallace, R., Elder, R. H. and Szabó, C. 
(2005) Potential role for 8-oxoguanine DNA glycosylase in regulating 
inflammation. FASEB J., 19, 290–292.
 122. Li, G., Yuan, K., Yan, C., et al. (2012) 8-Oxoguanine-DNA glycosylase 
1 deficiency modifies allergic airway inflammation by regulating STAT6 
and IL-4 in cells and in mice. Free Radic. Biol. Med., 52, 392–401.
 123. Fleming, A. M., Zhu, J., Ding, Y., Esders, S. and Burrows, C. J. (2019) 
Oxidative modification of guanine in a potential Z-DNA-forming 
sequence of a gene promoter impacts gene expression. Chem. Res. 
Toxicol., 32, 899–909.
 124. Zhu,  J., Fleming, A. M. and Burrows, C.  J. (2018) The RAD17 pro-
moter sequence contains a potential tail-dependent G-quadruplex that 
downregulates gene expression upon oxidative modification. ACS 
Chem. Biol., 13, 2577–2584.
 125. Redstone, S. C. J., Fleming, A. M. and Burrows, C. J. (2019) Oxidative 
modification of the potential G-quadruplex sequence in the PCNA gene 
promoter can turn on transcription. Chem. Res. Toxicol., 32, 437–446.
 126. Fleming, A. M., Zhu, J., Howpay Manage, S. A., and Burrows, C.  J. 
(2019) Human NEIL3 gene expression regulated by epigenetic-like oxi-
dative DNA modification. J. Am. Chem. Soc, 141, 11036–11049.
 127. Fleming, A. M., Zhu, J., Ding, Y., Visser, J. A., Zhu, J. and Burrows, C. J. 
(2018) Human DNA repair genes possess potential G-quadruplex 
sequences in their promoters and 5′-untranslated regions. Biochemistry, 
57, 991–1002.
 128. Gautier,  C. (2000) Compositional bias in DNA. Curr. Opin. Genet. 
Dev., 10, 656–661.
 129. Forneris, F., Binda, C., Vanoni, M. A., Mattevi, A. and Battaglioli, E. 
(2005) Histone demethylation catalysed by LSD1 is a flavin-dependent 
oxidative process. FEBS Lett., 579, 2203–2207.
 130. Boldogh, I., Hajas, G., Aguilera-Aguirre, L., Hegde, M. L., Radak, Z., 
Bacsi, A., Sur, S., Hazra, T. K. and Mitra, S. (2012) Activation of ras 








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
signaling pathway by 8-oxoguanine DNA glycosylase bound to its exci-
sion product, 8-oxoguanine. J. Biol. Chem., 287, 20769–20773.
 131. Vohhodina, J., Harkin, D. P. and Savage, K. I. (2016) Dual roles of DNA 
repair enzymes in RNA biology/post-transcriptional control. Wiley 
Interdiscip. Rev. RNA, 7, 604–619.
 132. Jobert, L. and Nilsen, H. (2014) Regulatory mechanisms of RNA func-
tion: emerging roles of DNA repair enzymes. Cell. Mol. Life Sci., 71, 
2451–2465.
 133. Antoniali, G., Malfatti, M. C. and Tell, G. (2017) Unveiling the non-
repair face of the base excision repair pathway in RNA processing: a 
missing link between DNA repair and gene expression? DNA Repair 
(Amst)., 56, 65–74.
 134. Tell, G., Wilson, D. M., III and Lee, C. H. (2010) Intrusion of a DNA 
repair protein in the RNome world: is this the beginning of a new era? 
Mol. Cell. Biol., 30, 366–371.
 135. Poletto, M., Vascotto, C., Scognamiglio, P. L., Lirussi, L., Marasco, D. 
and Tell, G. (2013) Role of the unstructured N-terminal domain of the 
hAPE1 (human apurinic/apyrimidinic endonuclease 1) in the modula-
tion of its interaction with nucleic acids and NPM1 (nucleophosmin). 
Biochem. J., 452, 545–557.
 136. Chohan, M., Mackedenski, S., Li, W. M. and Lee, C. H. (2015) Human 
apurinic/apyrimidinic endonuclease 1 (APE1) has 3′ RNA phosphatase 
and 3′ exoribonuclease activities. J. Mol. Biol., 427, 298–311.
 137. Zhang, C. and Peng, G. (2015) Non-coding RNAs: an emerging player 
in DNA damage response. Mutat. Res. Rev. Mutat. Res., 763, 202–211.
 138. D’Adda di Fagagna, F. (2014) A direct role for small non-coding RNAs 
in DNA damage response. Trends Cell Biol., 24,171–178.
 139. Su,  M., Wang,  H., Wang,  W., Wang,  Y., Ouyang,  L., Pan,  C., Xia,  L., 
Cao, D. and Liao, Q. (2018) LncRNAs in DNA damage response and re-
pair in cancer cells. Acta Biochim. Biophys. Sin. (Shanghai)., 50, 433–439.
 140. Poletto,  M., Lirussi,  L., Wilson,  D.  M., III and Tell,  G. (2014) 
Nucleophosmin modulates stability, activity, and nucleolar ac-
cumulation of base excision repair proteins. Mol. Biol. Cell, 25, 
1641–1652.
 141. Di Maso, V., Avellini, C., Crocè, L. S., et al. (2007) Subcellular localiza-
tion of APE1/Ref-1 in human hepatocellular carcinoma: possible prog-
nostic significance. Mol. Med., 13, 89–96.
 142. Nunomura, A., Moreira, P.  I., Castellani, R.  J., Lee, H. G., Zhu, X., 
Smith, M. A. and Perry, G. (2012) Oxidative damage to RNA in aging 
and neurodegenerative disorders. Neurotox. Res., 22, 231–248.
 143. Förstemann,  K. and Lingner,  J. (2005) Telomerase limits the extent of 
base pairing between template RNA and telomeric DNA. EMBO Rep., 6, 
361–366.
 144. Kahl,  G. (2015) DNA–RNA hybrid. The Dictionary of Genomics, 
Transcriptomics and Proteomics. The Dictionary of Genomics, 
Transcriptomics and Proteomics Science, pp. 1–1.
 145. Hamperl,  S. and Cimprich,  K.  A. (2014) The contribution of 
co-transcriptional RNA:DNA hybrid structures to DNA damage and 
genome instability. DNA Repair (Amst)., 19, 84–94.
 146. Brambati, A., Colosio, A., Zardoni, L., Galanti, L. and Liberi, G. (2015) 
Replication and transcription on a collision course: eukaryotic regulation 
mechanisms and implications for DNA stability. Front. Genet., 6, 166.
 147. Sassa, A., Yasui, M., and Honma, M. (2019) Current perspectives on 
mechanisms of ribonucleotide incorporation and processing in mam-
malian DNA. Genes Environ., 41, 3.
 148. Williams, J. S. and Kunkel, T. A. (2014) Ribonucleotides in DNA: ori-
gins, repair and consequences. DNA Repair (Amst)., 19, 27–37.
 149. Koh, K. D., Balachander,  S., Hesselberth,  J. R. and Storici,  F. (2015) 
Ribose-seq: global mapping of ribonucleotides embedded in genomic 
DNA. Nat. Methods, 12, 251–257.
 150. Hovatter, K. R. and Martinson, H. G. (1987) Ribonucleotide-induced 
helical alteration in DNA prevents nucleosome formation. Proc. Natl. 
Acad. Sci. U. S. A., 84, 1162–1166.
 151. Potenski, C. J. and Klein, H. L. (2014) How the misincorporation of 
ribonucleotides into genomic DNA can be both harmful and helpful to 
cells. Nucleic Acids Res., 42, 10226–10234.
 152. Kind, B., Wolf, C., Engel, K., Rapp, A., Cristina Cardoso, M. and Lee-
Kirsch, M. A. (2018) Single cell gel electrophoresis for the detection of 
genomic ribonucleotides. Methods Mol. Biol., 1672, 311–318.
 153. Meroni, A., Nava, G. M., Sertic, S., Plevani, P., Muzi-Falconi, M. and 
Lazzaro, F. (2018) Measuring the levels of ribonucleotides embedded in 
genomic DNA. Methods Mol. Biol., 1672, 319–327.
 154. Li,  Z., Zhang,  H.  X., Li,  Y., et  al. (2019) Method for quantifica-
tion of ribonucleotides and deoxyribonucleotides in human cells 
using (trimethylsilyl)diazomethane derivatization followed by liquid 
chromatography-tandem mass spectrometry. Anal. Chem., 91, 1019–
1026.
 155. Zhou,  Z.-X., Williams,  J.  S. and Kunkel,  T.  A. (2018) Studying 
ribonucleotide incorporation: strand-specific detection of 
ribonucleotides in the yeast genome and measuring ribonucleotide-
induced mutagenesis. J. Vis. Exp, 58020.
 156. Jinks-Robertson, S. and Klein, H. L. (2015) Ribonucleotides in DNA: 
hidden in plain sight. Nat. Struct. Mol. Biol., 22, 176–178.
 157. Gombolay, A. L., Vannberg, F. O. and Storici, F. (2019) Ribose-Map: 
a bioinformatics toolkit to map ribonucleotides embedded in genomic 
DNA. Nucleic Acids Res., 47, e5.
 158. Clausen, A. R., Lujan, S. A., Burkholder, A. B., et al. (2015) Tracking rep-
lication enzymology in vivo by genome-wide mapping of ribonucleotide 
incorporation. Nat. Struct. Mol. Biol., 22, 185–191.
 159. Daigaku,  Y., Keszthelyi,  A., Müller,  C.  A., Miyabe,  I., Brooks,  T., 
Retkute, R., Hubank, M., Nieduszynski, C. A. and Carr, A. M. (2015) 
A global profile of replicative polymerase usage. Nat. Struct. Mol. Biol., 
22, 192–198.
 160. Reijns, M. A., Rabe, B., Rigby, R. E., et al. (2012) Enzymatic removal of 
ribonucleotides from DNA is essential for mammalian genome integrity 
and development. Cell, 149, 1008–1022.
 161. Nick McElhinny, S. A., Kumar, D., Clark, A. B., Watt, D. L., Watts, B. E., 
Lundström, E. B., Johansson, E., Chabes, A. and Kunkel, T. A. (2010) 
Genome instability due to ribonucleotide incorporation into DNA. Nat. 
Chem. Biol., 6, 774–781.
 162. Joyce, C. M. (1997) Choosing the right sugar: how polymerases select a 
nucleotide substrate. Proc. Natl. Acad. Sci. U. S. A., 94, 1619–1622.
 163. Brown, J. A. and Suo, Z. (2011) Unlocking the sugar “steric gate” of 
DNA polymerases. Biochemistry, 50, 1135–1142.
 164. Nick  McElhinny,  S.  A., Watts,  B.  E., Kumar,  D., Watt,  D.  L., 
Lundström,  E.  B., Burgers,  P.  M., Johansson,  E., Chabes,  A. and 
Kunkel, T. A. (2010) Abundant ribonucleotide incorporation into DNA 
by yeast replicative polymerases. Proc. Natl. Acad. Sci. U. S. A., 107, 
4949–4954.
 165. Marasco, M., Li, W., Lynch, M. and Pikaard, C. S. (2017) Catalytic prop-
erties of RNA polymerases IV and V: accuracy, nucleotide incorporation 
and rNTP/dNTP discrimination. Nucleic Acids Res., 45, 11315–11326.
 166. Vaisman, A. and Woodgate, R. (2018) Ribonucleotide discrimination 
by translesion synthesis DNA polymerases. Crit. Rev. Biochem. Mol. 
Biol., 53, 382–402.
 167. Clausen, A. R., Zhang, S., Burgers, P. M., Lee, M. Y. and Kunkel, T. A. 
(2013) Ribonucleotide incorporation, proofreading and bypass by 
human DNA polymerase δ. DNA Repair (Amst)., 12, 121–127.
 168. Rossi, M. L. and Bambara, R. A. (2006) Reconstituted Okazaki frag-
ment processing indicates two pathways of primer removal. J. Biol. 
Chem., 281, 26051–26061.
 169. Chiu, H. C., Koh, K. D., Evich, M., Lesiak, A. L., Germann, M. W., 
Bongiorno, A., Riedo, E. and Storici, F. (2014) RNA intrusions change 
DNA elastic properties and structure. Nanoscale, 6, 10009–10017.
 170. Koh, K. D., Chiu, H. C., Riedo, E. and Storici, F. (2015) Measuring the 
elasticity of ribonucleotide(s)-containing DNA molecules using AFM. 
Methods Mol. Biol., 1297, 43–57.
 171. Evich,  M., Spring-Connell,  A.  M., Storici,  F. and Germann,  M.  W. 
(2016) Structural impact of single ribonucleotide residues in DNA. 
Chembiochem, 17, 1968–1977.
 172. Klein, H. L. (2017) Genome instabilities arising from ribonucleotides in 
DNA. DNA Repair (Amst)., 56, 26–32.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 173. Fu, I., Smith, D. J. and Broyde, S. (2019) Rotational and translational 
positions determine the structural and dynamic impact of a single 
ribonucleotide incorporated in the nucleosome. DNA Repair (Amst)., 
73, 155–163.
 174. Meroni, A., Mentegari, E., Crespan, E., Muzi-Falconi, M., Lazzaro, F. 
and Podestà, A. (2017) The incorporation of ribonucleotides induces 
structural and conformational changes in DNA. Biophys. J., 113, 1373–
1382.
 175. Sparks, J. L., Chon, H., Cerritelli, S. M., Kunkel, T. A., Johansson, E., 
Crouch,  R.  J. and Burgers,  P.  M. (2012) RNase H2-initiated 
ribonucleotide excision repair. Mol. Cell, 47, 980–986.
 176. Rydberg,  B. and Game,  J. (2002) Excision of misincorporated 
ribonucleotides in DNA by RNase H (type 2) and FEN-1 in cell-free 
extracts. Proc. Natl. Acad. Sci. U. S. A., 99, 16654–16659.
 177. Hiller,  B., Achleitner,  M., Glage,  S., Naumann,  R., Behrendt,  R. and 
Roers, A. (2012) Mammalian RNase H2 removes ribonucleotides from 
DNA to maintain genome integrity. J. Exp. Med., 209, 1419–1426.
 178. Cerritelli, S. M. and Crouch, R. J. (2009) Ribonuclease H: the enzymes 
in eukaryotes. FEBS J., 276, 1494–1505.
 179. Lazzaro,  F., Novarina,  D., Amara,  F., et  al. (2012) RNase H and 
postreplication repair protect cells from ribonucleotides incorporated 
in DNA. Mol. Cell, 45, 99–110.
 180. Pizzi, S., Sertic, S., Orcesi, S., Cereda, C., Bianchi, M., Jackson, A. P., 
Lazzaro,  F., Plevani,  P. and Muzi-Falconi,  M. (2015) Reduction of 
hRNase H2 activity in Aicardi-Goutières syndrome cells leads to repli-
cation stress and genome instability. Hum. Mol. Genet., 24, 649–658.
 181. Crow, Y. J., Leitch, A., Hayward, B. E., et al. (2006) Mutations in genes 
encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome 
and mimic congenital viral brain infection. Nat. Genet., 38, 910–916.
 182. Rabe, B. (2013) Aicardi-Goutières syndrome: clues from the RNase H2 
knock-out mouse. J. Mol. Med. (Berl)., 91, 1235–1240.
 183. Brzostek-Racine, S., Gordon, C., Van Scoy, S. and Reich, N. C. (2011) 
The DNA damage response induces IFN. J. Immunol., 187, 5336–5345.
 184. Tsukiashi,  M., Baba,  M., Kojima,  K., Himeda,  K., Takita,  T. and 
Yasukawa,  K. (2019) Construction and characterization of ribo-
nuclease H2 knockout NIH3T3 cells. J. Biochem., 165, 249–256.
 185. Uehara,  R., Cerritelli,  S.  M., Hasin,  N., Sakhuja,  K., London,  M., 
Iranzo,  J., Chon,  H., Grinberg,  A. and Crouch,  R.  J. (2018) Two 
RNase H2 mutants with differential rNMP processing activity reveal a 
threshold of ribonucleotide tolerance for embryonic development. Cell 
Rep., 25, 1135–1145.e5.
 186. Mottaghi-Dastjerdi,  N., Soltany-Rezaee-Rad,  M., Sepehrizadeh,  Z., 
Roshandel, G., Ebrahimifard, F. and Setayesh, N. (2015) Identification 
of novel genes involved in gastric carcinogenesis by suppression sub-
tractive hybridization. Hum. Exp. Toxicol., 34, 3–11.
 187. Aden, K., Bartsch, K., Dahl, J., et al. (2019) Epithelial RNase H2 main-
tains genome integrity and prevents intestinal tumorigenesis in mice. 
Gastroenterology, 156, 145.e19–159.e19.
 188. Hiller,  B., Hoppe,  A., Haase,  C., et  al. (2018) Ribonucleotide exci-
sion repair is essential to prevent squamous cell carcinoma of the skin. 
Cancer Res., 78, 5917–5926.
 189. Sayrac, S., Vengrova, S., Godfrey, E. L. and Dalgaard, J. Z. (2011) Iden-
tification of a novel type of spacer element required for imprinting in 
fission yeast. PLoS Genet., 7, e1001328.
 190. Brown,  J. A., Fiala, K. A., Fowler,  J. D., Sherrer, S. M., Newmister, S. A., 
Duym, W. W. and Suo, Z. (2010) A novel mechanism of sugar selection util-
ized by a human X-family DNA polymerase. J. Mol. Biol., 395, 282–290.
 191. Ruiz,  J.  F., Juárez,  R., García-Díaz,  M., Terrados,  G., Picher,  A.  J., 
González-Barrera, S., Fernández de Henestrosa, A. R. and Blanco, L. 
(2003) Lack of sugar discrimination by human Pol mu requires a single 
glycine residue. Nucleic Acids Res., 31, 4441–4449.
 192. Martin, M. J., Garcia-Ortiz, M. V., Esteban, V. and Blanco, L. (2013) 
Ribonucleotides and manganese ions improve non-homologous end 
joining by human Polμ. Nucleic Acids Res., 41, 2428–2436.
 193. Nick McElhinny, S. A. and Ramsden, D. A. (2003) Polymerase mu is 
a DNA-directed DNA/RNA polymerase. Mol. Cell. Biol., 23, 2309–
2315.
 194. Lujan,  S.  A., Williams,  J.  S., Clausen,  A.  R., Clark,  A.  B. and 
Kunkel, T. A. (2013) Ribonucleotides are signals for mismatch repair 
of leading-strand replication errors. Mol. Cell, 50, 437–443.
 195. Storici,  F., Bebenek,  K., Kunkel,  T.  A., Gordenin,  D.  A. and 
Resnick, M. A. (2007) RNA-templated DNA repair. Nature, 447, 338–
341.
 196. Shen, Y., Nandi, P., Taylor, M. B., Stuckey, S., Bhadsavle, H. P., Weiss, B. 
and Storici, F. (2011) RNA-driven genetic changes in bacteria and in 
human cells. Mutat. Res., 717, 91–98.
 197. Shen, Y., Koh, K. D., Weiss, B. and Storici, F. (2011) Mispaired rNMPs 
in DNA are mutagenic and are targets of mismatch repair and RNases 
H. Nat. Struct. Mol. Biol., 19, 98–104.
 198. Williams,  J.  S., Lujan,  S.  A. and Kunkel,  T.  A. (2016) Processing 
ribonucleotides incorporated during eukaryotic DNA replication. Nat. 
Rev. Mol. Cell Biol., 17, 350–363.
 199. Williams, J. S., Smith, D. J., Marjavaara, L., Lujan, S. A., Chabes, A. 
and Kunkel,  T.  A. (2013) Topoisomerase 1-mediated removal of 
ribonucleotides from nascent leading-strand DNA. Mol. Cell, 49, 1010–
1015.
 200. Capranico,  G., Marinello,  J. and Chillemi,  G. (2017) Type I  DNA 
topoisomerases. J. Med. Chem., 60, 2169–2192.
 201. Cho, J. E. and Jinks-Robertson, S. (2018) Topoisomerase I and genome 
stability: the good and the bad. Methods Mol. Biol., 1703, 21–45.
 202. Williams, J. S. and Kunkel, T. A. (2018) Studying topoisomerase 1-mediated 
damage at genomic ribonucleotides. Methods Mol. Biol., 1703, 241–257.
 203. Sekiguchi, J. and Shuman, S. (1997) Site-specific ribonuclease activity of 
eukaryotic DNA topoisomerase I. Mol. Cell, 1, 89–97.
 204. Potenski, C. J., Niu, H., Sung, P. and Klein, H. L. (2014) Avoidance of 
ribonucleotide-induced mutations by RNase H2 and Srs2-Exo1 mech-
anisms. Nature, 511, 251–254.
 205. Kim, N., Huang, S. N., Williams, J. S., Li, Y. C., Clark, A. B., Cho, J. E., 
Kunkel, T. A., Pommier, Y. and Jinks-Robertson, S. (2011) Mutagenic 
processing of ribonucleotides in DNA by yeast topoisomerase I. Science, 
332, 1561–1564.
 206. Li, F., Wang, Q., Seol, J. H., Che, J., Lu, X., Shim, E. Y., Lee, S. E. and 
Niu, H. (2019) Apn2 resolves blocked 3′ ends and suppresses Top1-
induced mutagenesis at genomic rNMP sites. Nat. Struct. Mol. Biol., 26, 
155–163.
 207. Zimmermann, M., Murina, O., Reijns, M. A. M., et al. (2018) CRISPR 
screens identify genomic ribonucleotides as a source of PARP-trapping 
lesions. Nature, 559, 285–289.
 208. Lindsey-Boltz, L. A., Kemp, M. G., Hu, J. and Sancar, A. (2015) Ana-
lysis of ribonucleotide removal from DNA by human nucleotide exci-
sion repair. J. Biol. Chem., 290, 29801–29807.
 209. Reardon, J. T. and Sancar, A. (2005) Nucleotide excision repair. Prog. 
Nucleic Acid Res. Mol. Biol., 79, 183–235.
 210. Vaisman,  A., McDonald,  J.  P., Huston,  D., Kuban,  W., Liu,  L., 
Van Houten, B. and Woodgate, R. (2013) Removal of misincorporated 
ribonucleotides from prokaryotic genomes: an unexpected role for nu-
cleotide excision repair. PLoS Genet., 9, e1003878.
 211. Cai, Y., Geacintov, N. E. and Broyde, S. (2014) Ribonucleotides as nu-
cleotide excision repair substrates. DNA Repair (Amst)., 13, 55–60.
 212. Randerath,  K., Reddy,  R., Danna,  T.  F., Watson,  W.  P., Crane,  A.  E. 
and Randerath, E. (1992) Formation of ribonucleotides in DNA modi-
fied by oxidative damage in vitro and in vivo. Characterization by 
32P-postlabeling. Mutat. Res., 275, 355–366.
 213. Kuznetsov,  N.  A., Koval,  V.  V., Zharkov,  D.  O., Nevinsky,  G.  A., 
Douglas, K. T. and Fedorova, O. S. (2005) Kinetics of substrate recog-
nition and cleavage by human 8-oxoguanine-DNA glycosylase. Nucleic 
Acids Res., 33, 3919–3931.
 214. Yamagata, Y. (2011) Structural basis for the recognition and removal of 
damaged bases from DNA by a DNA repair enzyme, 3-methyladenine 
DNA glycosylase from Escherichia coli. Nihon Kessho Gakkaishi, 
39,303–308.
 215. Fromme, J. C., Bruner, S. D., Yang, W., Karplus, M. and Verdine, G. L. 
(2003) Product-assisted catalysis in base-excision DNA repair. Nat. 
Struct. Biol., 10, 204–211.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 216. Malfatti, M. C., Henneke, G., Balachander, S., Koh, K. D., Newnam, G., 
Uehara,  R., Crouch,  R.  J., Storici,  F. and Tell,  G. (2019) Unlike the 
Escherichia coli counterpart, archaeal RNase HII cannot process ribose 
monophosphate abasic sites and oxidized ribonucleotides embedded in 
DNA. J. Biol. Chem., 294, 13061–13072.
 217. Berglund,  A.  K., Navarrete,  C., Engqvist,  M.  K., Hoberg,  E., 
Szilagyi,  Z., Taylor,  R.  W., Gustafsson,  C.  M., Falkenberg,  M. and 
Clausen,  A.  R. (2017) Nucleotide pools dictate the identity and fre-
quency of ribonucleotide incorporation in mitochondrial DNA. PLoS 
Genet., 13, e1006628.
 218. Kreisel, K., Engqvist, M. K. M. and Clausen, A. R. (2017) Simultaneous 
mapping and quantitation of ribonucleotides in human mitochondrial 
DNA. J. Vis. Exp., 56551.
 219. Moss,  C.  F., Dalla  Rosa,  I., Hunt,  L.  E., et  al. (2017) Aberrant 
ribonucleotide incorporation and multiple deletions in mitochondrial 
DNA of the murine MPV17 disease model. Nucleic Acids Res., 45, 
12808–12815.
 220. Forslund,  J.  M.  E., Pfeiffer,  A., Stojkovič,  G., Wanrooij,  P.  H. and 
Wanrooij, S. (2018) The presence of rNTPs decreases the speed of mito-
chondrial DNA replication. PLoS Genet., 14, e1007315.
 221. Wanrooij, P. H., Engqvist, M. K. M., Forslund, J. M. E., Navarrete, C., 
Nilsson, A. K., Sedman, J., Wanrooij, S., Clausen, A. R. and Chabes, A. 
(2017) Ribonucleotides incorporated by the yeast mitochondrial DNA 
polymerase are not repaired. Proc. Natl. Acad. Sci. U.  S. A., 114, 
12466–12471.
 222. Leguisamo,  N.  M., Gloria,  H.  C., Kalil,  A.  N., Martins,  T.  V., 
Azambuja, D. B., Meira, L. B. and Saffi, J. (2017) Base excision repair 
imbalance in colorectal cancer has prognostic value and modulates re-
sponse to chemotherapy. Oncotarget, 8, 54199–54214.
 223. Shah,  F., Logsdon,  D., Messmann,  R.  A., Fehrenbacher,  J.  C., 
Fishel, M. L. and Kelley, M. R. (2018) Exploiting the Ref-1-APE1 node 
in cancer signaling and other diseases: from bench to clinic. npj Precis. 
Oncol., 1.
 224. Yuan, C. L., He, F., Ye, J. Z., et al. (2017) APE1 overexpression is asso-
ciated with poor survival in patients with solid tumors: a meta-analysis. 
Oncotarget, 8, 59720–59728.
 225. Kumar,  M., Shukla,  V.  K., Misra,  P.  K. and Raman,  M.  J. (2018) 
Dysregulated expression and subcellular localization of base excision 
repair (BER) pathway enzymes in gallbladder cancer. Int. J. Mol. Cell. 
Med., 7, 119–132.
 226. Di Maso, V., Mediavilla, M. G., Vascotto, C., Lupo, F., Baccarani, U., 
Avellini, C., Tell, G., Tiribelli, C. and Crocè, L. S. (2015) Transcrip-
tional up-regulation of APE1/Ref-1 in hepatic tumor: role in hep-
atocytes resistance to oxidative stress and apoptosis. PLoS One, 10, 
e0143289.
 227. Sun, Z., Zhu, Y., Aminbuhe, Fan, Q., Peng,  J. and Zhang, N. (2018) 
Differential expression of APE1 in hepatocellular carcinoma and the 
effects on proliferation and apoptosis of cancer cells. Biosci. Trends, 12, 
456–462.
 228. Jiang, Y., Zhou, S., Sandusky, G. E., Kelley, M. R. and Fishel, M. L. 
(2010) Reduced expression of DNA repair and redox signaling protein 
APE1/Ref-1 impairs human pancreatic cancer cell survival, prolifer-
ation, and cell cycle progression. Cancer Invest., 28, 885–895.
 229. Juhnke,  M., Heumann,  A., Chirico,  V., et  al. (2017) Apurinic/
apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an inde-
pendent prognostic marker in prostate cancer without TMPRSS2:ERG 
fusion. Mol. Carcinog., 56, 2135–2145.
 230. Hong, J., Chen, Z., Peng, D., Zaika, A., Revetta, F., Washington, M. K., 
Belkhiri, A. and El-Rifai, W. (2016) APE1-mediated DNA damage re-
pair provides survival advantage for esophageal adenocarcinoma cells 
in response to acidic bile salts. Oncotarget, 7, 16688–16702.
 231. Qing, Y., Li, Q., Ren, T., et al. (2015) Upregulation of PD-L1 and APE1 
is associated with tumorigenesis and poor prognosis of gastric cancer. 
Drug Des. Devel. Ther., 9, 901–909.
 232. Silva, L. P., Santana, T., Sedassari, B. T., de Sousa, S. M., Sobral, A. P. V., 
Freitas, R. A., Barboza, C. A. G. and de Souza, L. B. (2017) Apurinic/
apyrimidinic endonuclease 1 (APE1) is overexpressed in malignant 
transformation of salivary gland pleomorphic adenoma. Eur. Arch. 
Otorhinolaryngol., 274, 3203–3209.
 233. Yang, X., Peng, Y., Jiang, X., et al. (2018) The regulatory role of APE1 
in epithelial-to-mesenchymal transition and in determining EGFR-TKI 
responsiveness in non-small-cell lung cancer. Cancer Med., 7, 4406–
4419.
 234. Wen,  X., Lu,  R., Xie,  S., Zheng,  H., Wang,  H., Wang,  Y., Sun,  J., 
Gao, X. and Guo, L. (2016) APE1 overexpression promotes the pro-
gression of ovarian cancer and serves as a potential therapeutic target. 
Cancer Biomark., 17, 313–322.
 235. Sheng,  Q., Zhang,  Y., Wang,  R., Zhang,  J., Chen,  B., Wang,  J., 
Zhang, W. and Xin, X. (2012) Prognostic significance of APE1 cyto-
plasmic localization in human epithelial ovarian cancer. Med. Oncol., 
29, 1265–1271.
 236. Kakolyris,  S., Kaklamanis,  L., Engels,  K., Turley,  H., Hickson,  I.  D., 
Gatter, K. C. and Harris, A. L. (1997) Human apurinic endonuclease 1 
expression in a colorectal adenoma-carcinoma sequence. Cancer Res., 
57, 1794–1797.
 237. Lou, D., Zhu, L., Ding, H., Dai, H. Y. and Zou, G. M. (2014) Aberrant 
expression of redox protein Ape1 in colon cancer stem cells. Oncol. 
Lett., 7, 1078–1082.
 238. Noike, T., Miwa, S., Soeda, J., Kobayashi, A. and Miyagawa, S. (2008) 
Increased expression of thioredoxin-1, vascular endothelial growth 
factor, and redox factor-1 is associated with poor prognosis in patients 
with liver metastasis from colorectal cancer. Hum. Pathol., 39, 201–
208.
 239. Chen,  T., Liu,  C., Lu,  H., Yin,  M., Shao,  C., Hu,  X., Wu,  J. and 
Wang,  Y. (2017) The expression of APE1 in triple-negative breast 
cancer and its effect on drug sensitivity of olaparib. Tumour Biol., 39, 
1010428317713390.
 240. Abdel-Fatah,  T.  M., Perry,  C., Moseley,  P., Johnson,  K., Arora,  A., 
Chan, S., Ellis,  I. O. and Madhusudan, S. (2014) Clinicopathological 
significance of human apurinic/apyrimidinic endonuclease 1 (APE1) 
expression in oestrogen-receptor-positive breast cancer. Breast Cancer 
Res. Treat., 143, 411–421.
 241. Wang, Q., Xiao, H., Luo, Q., Li, M., Wei, S., Zhu, X., Xiao, H. and 
Chen,  L. (2016) Low APE1/Ref-1 expression significantly correl-
ates with MGMT promoter methylation in patients with high-grade 
gliomas. Int. J. Clin. Exp. Pathol., 9,9562–9568.
 242. Hudson,  A.  L., Parker,  N.  R., Khong,  P., et  al. (2018) Glioblastoma 
recurrence correlates with increased APE1 and polarization toward an 
immuno-suppressive microenvironment. Front. Oncol., 8, 314.
 243. Sengupta, S., Mantha, A. K., Song, H., Roychoudhury, S., Nath, S., Ray, S. 
and Bhakat, K. K. (2016) Elevated level of acetylation of APE1 in tumor cells 
modulates DNA damage repair. Oncotarget, 7, 75197–75209.
 244. Marasco,  D., Tell,  G., Poletto,  M., Damante,  G., Loreto,  C.  Di., 
Poletto,  E., and Puglisi,  F. (2012) Acetylation on critical lysine res-
idues of apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative 
breast cancers. Biochem. Biophys. Res. Commun., 424,34–39.
 245. Ding,  J., Fishel,  M.  L., Reed,  A.  M., McAdams,  E., Czader,  M.  B., 
Cardoso, A. A. and Kelley, M. R. (2017) Ref-1/APE1 as a transcrip-
tional regulator and novel therapeutic target in pediatric T-cell leu-
kemia. Mol. Cancer Ther., 16, 1401–1411.
 246. Poletto,  M., Malfatti,  M.  C., Dorjsuren,  D., et  al. (2016) Inhibitors 
of the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin 
(NPM1) interaction that display anti-tumor properties. Mol. Carcinog., 
55, 688–704.
 247. Fan,  X., Wen,  L., Li,  Y., Lou,  L., Liu,  W. and Zhang,  J. (2017) The 
expression profile and prognostic value of APE/Ref-1 and NPM1 in 
high-grade serous ovarian adenocarcinoma. APMIS, 125, 857–862.
 248. Kalitin, N. N., Chernykh, Y. B. and Buravtsova, I. V. (2017) Compara-
tive analysis of quantitative parameters of expression of the retinoic 
acid nuclear receptor RARα gene and APE1/YB-1/MDR1 pattern genes 
in patients with newly detected multiple myeloma. Bull. Exp. Biol. 
Med., 164, 90–94.
 249. Fishel, M. L., Colvin, E. S., Luo, M., Kelley, M. R. and Robertson, K. A. 
(2010) Inhibition of the redox function of APE1/Ref-1 in myeloid leu-








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
kemia cell lines results in a hypersensitive response to retinoic acid-
induced differentiation and apoptosis. Exp. Hematol., 38, 1178–1188.
 250. Abbotts, R., Jewell, R., Nsengimana, J., et al. (2014) Targeting human 
apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin 
homolog (PTEN) deficient melanoma cells for personalized therapy. 
Oncotarget, 5, 3273–3286.
 251. Liang, W., Wei, X., Li, Q., et al. (2017) MicroRNA-765 enhances the 
anti-angiogenic effect of CDDP via APE1 in osteosarcoma. J. Cancer, 8, 
1542–1551.
 252. Dai,  N., Qing,  Y., Cun,  Y., et  al. (2018) miR-513a-5p regulates 
radiosensitivity of osteosarcoma by targeting human apurinic/
apyrimidinic endonuclease. Oncotarget, 9, 25414–25426.
 253. Dziaman, T., Banaszkiewicz, Z., Roszkowski, K., et al. (2014) 8-Oxo-
7,8-dihydroguanine and uric acid as efficient predictors of survival in 
colon cancer patients. Int. J. Cancer, 134, 376–383.
 254. Abdel-Fatah,  T.  M., Albarakati,  N., Bowell,  L., et  al. (2013) Single-
strand selective monofunctional uracil-DNA glycosylase (SMUG1) de-
ficiency is linked to aggressive breast cancer and predicts response to 
adjuvant therapy. Breast Cancer Res. Treat., 142, 515–527.
 255. Azambuja,  D.  B., Leguisamo,  N.  M., Gloria,  H.  C., Kalil,  A.  N., 
Rhoden, E. and Saffi,  J. (2018) Prognostic impact of changes in base 
excision repair machinery in sporadic colorectal cancer. Pathol. Res. 
Pract., 214, 64–71.
 256. Lange, S. S., Takata, K. and Wood, R. D. (2011) DNA polymerases and 
cancer. Nat. Rev. Cancer, 11, 96–110.
 257. Wang, X., Hickey, R. J., Malkas, L. H., et al. (2011) Elevated expres-
sion of cancer-associated proliferating cell nuclear antigen in high-grade 
prostatic intraepithelial neoplasia and prostate cancer. Prostate, 71, 
748–754.
 258. Malkas, L. H., Herbert, B. S., Abdel-Aziz, W., et al. (2006) A cancer-
associated PCNA expressed in breast cancer has implications as a po-
tential biomarker. Proc. Natl. Acad. Sci. U. S. A., 103, 19472–19477.
 259. Abdel-Fatah, T. M., Russell, R., Albarakati, N., et al. (2014) Genomic 
and protein expression analysis reveals flap endonuclease 1 (FEN1) as 
a key biomarker in breast and ovarian cancer. Mol. Oncol., 8, 1326–
1338.
 260. Nikolova,  T., Christmann,  M. and Kaina,  B. (2009) FEN1 is 
overexpressed in testis, lung and brain tumors. Anticancer Res., 29, 
2453–2459.
 261. Chen, X., Legrand, A. J., Cunniffe, S., Hume, S., Poletto, M., Vaz, B., 
Ramadan, K., Yao, D. and Dianov, G. L. (2018) Interplay between base 
excision repair protein XRCC1 and ALDH2 predicts overall survival in 
lung and liver cancer patients. Cell. Oncol. (Dordr)., 41, 527–539.
 262. Sun,  D., Urrabaz,  R., Nguyen,  M., Marty,  J., Stringer,  S., Cruz,  E., 
Medina-Gundrum, L. and Weitman, S. (2001) Elevated expression of 
DNA ligase I in human cancers. Clin. Cancer Res., 7, 4143–4148.
 263. Wyatt, M. D. and Wilson, D. M., III. (2009) Participation of DNA re-
pair in the response to 5-fluorouracil. Cell. Mol. Life Sci., 66, 788–799.
 264. Vodenkova, S., Jiraskova, K., Urbanova, M., et al. (2018) Base excision 
repair capacity as a determinant of prognosis and therapy response in 
colon cancer patients. DNA Repair (Amst)., 72, 77–85.
 265. Chaim, I. A., Nagel, Z. D., Jordan, J. J., Mazzucato, P., Ngo, L. P. and 
Samson, L. D. (2017) In vivo measurements of interindividual differ-
ences in DNA glycosylases and APE1 activities. Proc. Natl. Acad. Sci. 
U. S. A., 114, E10379–E10388.
 266. Hu, J., Liu, M. H., Li, Y., Tang, B. and Zhang, C. Y. (2018) Simultan-
eous sensitive detection of multiple DNA glycosylases from lung cancer 
cells at the single-molecule level. Chem. Sci., 9, 712–720.
 267. Köberle, B., Koch, B., Fischer, B. M. and Hartwig, A. (2016) Single nu-
cleotide polymorphisms in DNA repair genes and putative cancer risk. 
Arch. Toxicol., 90, 2369–2388.
 268. Ray, D. and Kidane, D. (2016) Gut microbiota imbalance and base ex-
cision repair dynamics in colon cancer. J. Cancer, 7, 1421–1430.
 269. Kiwerska, K. and Szyfter, K. (2019) DNA repair in cancer initiation, 
progression, and therapy-a double-edged sword. J. Appl. Genet., 60, 
329–334.
 270. Liu,  J., Zheng,  B., Li,  Y., Yuan,  Y. and Xing,  C. (2019) Genetic 
polymorphisms of DNA repair pathways in sporadic colorectal carcino-
genesis. J. Cancer, 10,1417–1433.
 271. Miyaishi, A., Osawa, K., Osawa, Y., et al. (2009) MUTYH Gln324His 
gene polymorphism and genetic susceptibility for lung cancer in a Jap-
anese population. J. Exp. Clin. Cancer Res., 28, 10.
 272. Zhang, Y., He, B. S., Pan, Y. Q., Xu, Y. Q. and Wang, S. K. (2011) Asso-
ciation of OGG1 Ser326Cys polymorphism with colorectal cancer risk: 
a meta-analysis. Int. J. Colorectal Dis., 26, 1525–1530.
 273. Lai, C. Y., Hsieh, L. L., Tang, R., Santella, R. M., Chang-Chieh, C. R. 
and Yeh, C. C. (2016) Association between polymorphisms of APE1 and 
OGG1 and risk of colorectal cancer in Taiwan. World J. Gastroenterol., 
22, 3372–3380.
 274. Gu, D., Wang, M., Zhang, Z. and Chen, J. (2010) Lack of association 
between the hOGG1 Ser326Cys polymorphism and breast cancer risk: 
evidence from 11 case–control studies. Breast Cancer Res. Treat., 122, 
527–531.
 275. Ali,  K., Mahjabeen,  I., Sabir,  M., Mehmood,  H. and Kayani,  M.  A. 
(2015) OGG1 mutations and risk of female breast cancer: meta-
analysis and experimental data. Dis. Markers, 2015, 690878.
 276. Ramaniuk,  V.  P., Nikitchenko,  N.  V., Savina,  N.  V., Kuzhir,  T.  D., 
Rolevich, A. I., Krasny, S. A., Sushinsky, V. E. and Goncharova, R. I. 
(2014) Polymorphism of DNA repair genes OGG1, XRCC1, XPD and 
ERCC6 in bladder cancer in Belarus. Biomarkers, 19, 509–516.
 277. Smal,  M.  P., Kuzhir,  T.  D., Savina,  N.  V., Nikitchenko,  N.  V., 
Rolevich, A. I., Krasny, S. A. and Goncharova, R. I. (2018) BER gene 
polymorphisms associated with key molecular events in bladder cancer. 
Exp. Oncol., 40, 288–298.
 278. Stanczyk,  M., Sliwinski,  T., Cuchra,  M., Zubowska,  M., Bielecka-
Kowalska,  A., Kowalski,  M., Szemraj,  J., Mlynarski,  W. and 
Majsterek,  I. (2011) The association of polymorphisms in DNA base 
excision repair genes XRCC1, OGG1 and MUTYH with the risk of 
childhood acute lymphoblastic leukemia. Mol. Biol. Rep., 38, 445–451.
 279. Gotoh, N., Saitoh, T., Takahashi, N., et al. (2018) Association between 
OGG1 S326C CC genotype and elevated relapse risk in acute myeloid 
leukemia. Int. J. Hematol., 108, 246–253.
 280. Jiraskova,  K., Hughes,  D.  J., Brezina,  S., et  al. (2019) Functional 
polymorphisms in DNA repair genes are associated with sporadic colo-
rectal cancer susceptibility and clinical outcome. Int. J. Mol. Sci., 20, 97.
 281. Przybylowska,  K., Kabzinski,  J., Sygut,  A., Dziki,  L., Dziki,  A. and 
Majsterek, I. (2013) An association selected polymorphisms of XRCC1, 
OGG1 and MUTYH gene and the level of efficiency oxidative DNA 
damage repair with a risk of colorectal cancer. Mutat. Res., 745-746, 
6–15.
 282. Zhou, X., Wei, L., Jiao, G., Gao, W., Ying, M., Wang, N., Wang, Y. 
and Liu, C. (2015) The association between the APE1 Asp148Glu poly-
morphism and prostate cancer susceptibility: a meta-analysis based on 
case–control studies. Mol. Genet. Genomics, 290, 281–288.
 283. Mattar, M. A. M., Zekri, A. R. N., Hussein, N., Morsy, H., Esmat, G., 
and Amin, M.A. (2018) Polymorphisms of base-excision repair genes 
and the hepatocarcinogenesis. Gene, 675,62–68.
 284. Hadi, M. Z., Coleman, M. A., Fidelis, K., Mohrenweiser, H. W. and 
Wilson, D. M. III. (2000) Functional characterization of Ape1 variants 
identified in the human population. Nucleic Acids Res., 28, 3871–3879.
 285. Hsieh, W. C., Lin, C., Chen, D. R., et al. (2017) Genetic polymorphisms 
in APE1 Asp148Glu(rs3136820) as a modifier of the background levels 
of abasic sites in human leukocytes derived from breast cancer patients 
and controls. Breast Cancer, 24, 420–426.
 286. Dai, Z. J., Wang, X. J., Kang, A. J., et al. (2014) Association between 
APE1 single nucleotide polymorphism (rs1760944) and cancer risk: a 
meta-analysis based on 6,419 cancer cases and 6,781 case-free controls. 
J. Cancer, 5, 253–259.
 287. Kiuru,  A., Lindholm,  C., Heinävaara,  S., et  al. (2008) XRCC1 and 
XRCC3 variants and risk of glioma and meningioma. J. Neurooncol., 
88, 135–142.
 288. Li, Y., Li, S., Wu, Z., et al. (2013) Polymorphisms in genes of APE1, 
PARP1, and XRCC1: risk and prognosis of colorectal cancer in a 
Northeast Chinese population. Med. Oncol., 30, 505.
 289. Nissar,  S., Sameer,  A.  S., Rasool,  R., Chowdri,  N.  A. and Rashid,  F. 
(2015) Polymorphism of the DNA repair gene XRCC1 (Arg194Trp) 
and its role in colorectal cancer in Kashmiri population: a case control 
study. Asian Pac. J. Cancer Prev., 16, 6385–6390.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
 290. Meng,  Q., Wang,  S., Tang,  W., et  al. (2017) XRCC1 mediated the 
development of cervival cancer through a novel Sp1/Krox-20 swich. 
Oncotarget, 8, 86217–86226.
 291. Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., 
Weller,  M. and Wick,  W. (2008) Mechanisms of chemoresistance to 
alkylating agents in malignant glioma. Clin. Cancer Res., 14, 2900–
2908.
 292. Visnes, T., Grube, M., Hanna, B. M. F., Benitez-Buelga, C., Cázares-
Körner, A. and Helleday, T. (2018) Targeting BER enzymes in cancer 
therapy. DNA Repair (Amst)., 71, 118–126.
 293. Li, B., Song, T. N., Wang, F. R., Yin, C., Li, Z., Lin, J. P., Meng, Y. Q., 
Feng,  H.  M. and Jing,  T. (2019) Tumor-derived exosomal HMGB1 
promotes esophageal squamous cell carcinoma progression through 
inducing PD1+ TAM expansion. Oncogenesis, 8, 17.
 294. Gao, Q., Wang, S., Chen, X., et al. (2019) Cancer-cell-secreted CXCL11 
promoted CD8 + T cells infiltration through docetaxel-induced-release 
of HMGB1 in NSCLC. J. Immunother. Cancer, 7, 42.
 295. Liu, Y., Prasad, R., and Wilson,  S. H. (2010) HMGB1: roles in base 
excision repair and related function. Biochim. Biophys. Acta., 1799, 
119–130.
 296. Paudel, Y. N., Angelopoulou, E., Piperi, C., Balasubramaniam, V. R. M. T., 
Othman, I. and Shaikh, M. F. (2019) Enlightening the role of high mo-
bility group box 1 (HMGB1) in inflammation: updates on receptor 
signalling. Eur. J. Pharmacol., 858, 172487.
 297. Tang, D., Kang, R., Zeh, H. J. and Lotze, M. T. (2011) High-mobility 
group box 1, oxidative stress, and disease. Antioxid. Redox Signal., 14, 
1315–1335.
 298. Yu,  Y., Tang,  D. and Kang,  R. (2015) Oxidative stress-mediated 
HMGB1 biology. Front. Physiol., 6: 93.
 299. Sheller-Miller, S., Urrabaz-Garza, R., Saade, G. and Menon, R. (2017) 
Damage-associated molecular pattern markers HMGB1 and cell-free 
fetal telomere fragments in oxidative-stressed amnion epithelial cell-
derived exosomes. J. Reprod. Immunol., 123, 3–11.
 300. Buoncervello, M., Borghi, P., Romagnoli, G., Spadaro, F., Belardelli, F., 
Toschi, E. and Gabriele, L. (2012) Apicidin and docetaxel combination 
treatment drives CTCFL expression and HMGB1 release acting as po-
tential antitumor immune response inducers in metastatic breast cancer 
cells. Neoplasia, 14, 855–867.
 301. Malhotra,  V. (2013) Unconventional protein secretion: an evolving 
mechanism. EMBO J., 32, 1660–1664.
 302. Frye, B. C., Halfter, S., Djudjaj, S., et al. (2009) Y-box protein-1 is ac-
tively secreted through a non-classical pathway and acts as an extracel-
lular mitogen. EMBO Rep., 10, 783–789.
 303. Russo, D., Arturi, F., Bulotta, S., Pellizzari, L., Filetti, S., Manzini, G., 
Damante, G. and Tell, G. (2001) ApeI/Ref-I expression and cellular lo-
calization in human thyroid carcinoma cell lines. J. Endocrinol. Invest., 
24, RC10–RC12.
 304. Bobola, M. S., Blank, A., Berger, M. S., Stevens, B. A. and Silber, J. R. 
(2001) Apurinic/apyrimidinic endonuclease activity is elevated in 
human adult gliomas. Clin. Cancer Res., 7, 3510–3518.
 305. Puglisi, F., Barbone, F., Tell, G., et al. (2002) Prognostic role of Ape/
Ref-1 subcellular expression in stage I–III breast carcinomas. Oncol. 
Rep., 9, 11–17.
 306. Bendtsen, J. D., Jensen, L. J., Blom, N., Von Heijne, G. and Brunak, S. 
(2004) Feature-based prediction of non-classical and leaderless protein 
secretion. Protein Eng. Des. Sel., 17, 349–356.
 307. Park, M.  S., Lee, Y. R., Choi,  S., Joo, H. K., Cho, E.  J., Kim, C.  S., 
Park,  J. B., Jo, E. K. and Jeon, B. H. (2013) Identification of plasma 
APE1/Ref-1 in lipopolysaccharide-induced endotoxemic rats: implica-
tion of serological biomarker for an endotoxemia. Biochem. Biophys. 
Res. Commun., 435, 621–626.
 308. Choi, S., Lee, Y. R., Park, M. S., et al. (2013) Histone deacetylases in-
hibitor trichostatin A modulates the extracellular release of APE1/Ref-
1. Biochem. Biophys. Res. Commun., 435, 403–407.
 309. Lee, Y. R., Kim, K. M., Jeon, B. H. and Choi, S. (2015) Extracellularly 
secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer 
cells via RAGE binding, which is mediated through acetylation. Cancer 
Res., 76,4422–4422.
 310. Nath,  S., Roychoudhury,  S., Kling,  M.  J., Song,  H., Biswas,  P., 
Shukla, A., Band, H., Joshi, S. and Bhakat, K. K. (2017) The extracel-
lular role of DNA damage repair protein APE1 in regulation of IL-6 
expression. Cell. Signal., 39, 18–31.
 311. Pascut,  D., Sukowati,  C.  H.  C., Antoniali,  G., et  al. (2019) Serum 
AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular car-
cinoma. Oncotarget, 10, 383–394.
 312. Kuilman,  T., Michaloglou,  C., Vredeveld,  L.  C., Douma,  S., 
van  Doorn,  R., Desmet,  C.  J., Aarden,  L.  A., Mooi,  W.  J. and 
Peeper,  D.  S. (2008) Oncogene-induced senescence relayed by an 
interleukin-dependent inflammatory network. Cell, 133, 1019–1031.
 313. Tanner, K. and Gottesman, M. M. (2015) Beyond 3D culture models of 
cancer. Sci. Transl. Med., 7, 283ps9.
 314. Abbott, A. (2003) Cell culture: biology’s new dimension. Nature, 424, 
870–872.
 315. Leushacke, M. and Barker, N. (2014) Ex vivo culture of the intestinal 
epithelium: strategies and applications. Gut, 63, 1345–1354.
 316. Ohta, Y. and Sato, T. (2014) Intestinal tumor in a dish. Front. Med. 
(Lausanne)., 1, 14.
 317. Cristobal, A., van den Toorn, H. W. P., van de Wetering, M., Clevers, H., 
Heck, A. J. R. and Mohammed, S. (2017) Personalized proteome profiles 
of healthy and tumor human colon organoids reveal both individual di-
versity and basic features of colorectal cancer. Cell Rep., 18, 263–274.
 318. Van De Wetering, M., Francies, H. E., Francis, J. M., et al. (2015) Pro-
spective derivation of a living organoid biobank of colorectal cancer 
patients. Cell, 161,933–945.
 319. Drost,  J., van  Boxtel,  R., Blokzijl,  F., et  al. (2017) Use of CRISPR-
modified human stem cell organoids to study the origin of mutational 
signatures in cancer. Science, 358, 234–238.
 320. Francies,  H.  E., Barthorpe,  A., McLaren-Douglas,  A., Barendt,  W.  J. 
and Garnett, M. J. (2019) Erratum to: drug sensitivity assays of human 
cancer organoid cultures. Methods Mol. Biol., 1576, 353.
 321. Codrich, M., Comelli, M., Malfatti, M. C., et al. (2019) Inhibition of 
APE1-endonuclease activity affects cell metabolism in colon cancer cells 
via a p53-dependent pathway. DNA Repair (Amst)., 82, 102675.
 322. Li, T., Wernersson, R., Hansen, R. B., et  al. (2017) A scored human 
protein–protein interaction network to catalyze genomic interpretation. 
Nat. Methods, 14, 61–64.








utage/gez051/5681537 by guest on 22 D
ecem
ber 2019
